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Introduction: Host genetic variation is an important determinant of HIV infection, disease 
progression and HIV-associated neurocognitive deficits. However, there is no sufficient 
knowledge on the role of genetic variants especially among African populations. This study is 
focused on investigating variation in HIV/AIDS restriction genes; CCR2, CX3CR1, SDF1, 
RANTES, APOBEC3G and MBL2 and their possible role in HIV infection and neurocognitive 
function among children born to HIV infected mothers, recruited in Harare, Zimbabwe. 
Methods: A total of 116 children comprising of 73 perinatally exposed to HIV (34 who were 
born infected and 39 who were uninfected) and 43 unexposed controls were recruited in 
2011(at ages 7-9 years) from a cohort of mother-baby pairs that has been followed up since 
2002. The demographic characteristics of the recruited children were captured from their 
medical records. A McCarthy Scale of Children‟s Abilities (MSCA) was administered to 
determine each child‟s neurocognitive status. Genotyping for allelic variants was done using 
PCR-RFLP, SNaPshot® and Sanger DNA sequencing. Statistical analysis was carried out to 
determine association between genotypes, HIV status and neurocognitive function. 
Results: Baseline allele frequencies were established for 23 genetic variants in this 
Zimbabwean population and these included the discovery of a novel MBL2 -595G>A SNP. 
The distribution of the following genotypes and genotype combinations were significantly 
different when compared between the HIV-infected and HIV-uninfected groups, both 
perinatally exposed to HIV; CCR2 190G/A (P=0.02), CCR2 190G/A-CX3CR1 745G/G 
(P=0.0002), CCR2 190G/A-APOBEC3G 557A/A (P=0.015), MBL2 -221G/G-+4C/T 
(P=0.03) occurring in 15% v 39%, 0% v 33%, 0% v 17% and 44% v 22%, respectively. In 
addition, haplotypes were generated for APOBEC3G. The haplotype C-G-G-C-C with regard 
to -571G>C, -90C>G, 557G>A, 197T>C and 199C>G SNPs was present in 6% of HIV 
infected group but was not observed in the uninfected group (P=0.007).  We also observed 
that the MBL2 genotypes +4C/C (P=0.03) and -221C/G (P=0.02) were significantly 
associated with poor cognitive ability regardless of HIV status. 
Conclusion: The observation of different genetic variants or combinations of genotypes 
between the HIV-exposed and infected group and that of the HIV-exposed but uninfected 
group may be a pointer to critical pathways in differential HIV susceptibility. Exposure and 
infection with HIV is controlled by a multitude of genes/processes, thus, SNPs are unlikely to 
show statistically significant effects individually and may be more useful in a multifactorial 
model, as observed from comparisons of genotype combinations and haplotypes. The role of 
host genetic variation on neurocognitive function remains disputed but our observations 
suggest innate immune factors such as MBL2 may have a pronounced effect. Therefore, it 
may be possible to genotype for a suite of genes and use them as markers of either HIV 
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1 CHAPTER ONE: BACKGROUND 
 
1.1 Introduction 
Almost three decades after its discovery, human immune-deficiency virus (HIV) remains a 
major health burden in the world. At the end of year 2011, the World Health Organisation 
(WHO) reported an estimated 34 million people to be living with HIV worldwide . The wide 
use of antiretroviral therapy (ART) has significantly lowered the number of deaths and 
morbidities related to HIV/AIDS. Despite this, the pandemic currently contributes almost 
two million deaths annually (WHO 2011). According  to the Joint United Nations 
Programme on HIV/AIDS (UNAIDS 2010), sub-Saharan Africa (SSA) is the worst affected 
region with an estimated 70% of the world‟s HIV cases living in the region yet it carries only 
10% of the world population . Figure 1.1 is a map showing the distribution of HIV cases 
across the world. 
  
Figure 1.1: World map showing the distribution of HIV cases in WHO regions. Sub-Saharan 













An estimated 60% of the 22 million HIV cases in SSA are women (UNAIDS 2010). Most of 
the HIV-infected women fall within the reproductive age group of 15-49 years, thus, the 
number of children perinatally exposed to HIV is very high (UNAIDS 2010). This increases 
chances of mother-to-child transmission (MTCT) of HIV. Generally, the rate of HIV MTCT 
ranges from about 10-40% in the absence of intervention (De Cock et al. 2000). The use of 
ART, avoidance of breastfeeding and alternative delivery methods may reduce MTCT to 
almost 2% as witnessed in the developed world (Mofenson et al. 2002). However, these 
practices are largely impracticable in the developing world therefore MTCT remains high in 
SSA accounting for up to 90% of paediatric HIV infections. In 2010 alone, there were 400 
000 infants who were born HIV-infected worldwide (UNAIDS 2010).  
The countries worst affected by HIV in SSA are Swaziland, Botswana, Lesotho, South 
Africa, Namibia, Zambia and Zimbabwe. At least 10% of the population in each of these 
countries is HIV-infected with Swaziland leading the pack with a prevalence of more than 
25% (UNAIDS 2010). Zimbabwe noted its first HIV case in 1985 and by the end of the 
1980s, the prevalence had risen to about 10% (UNAIDS. 2005). This was the beginning of an 
escalation of the deadly disease in the country with figures reaching beyond 25% in 1997 as 
reported by the United Nations General Assembly Special Session (UNGASS 2010). The 
country has since witnessed a gradual drop in the HIV prevalence to 14% in 2010 according 
to the Zimbabwe Demographic and Healthy Survey 2010. More than 10% of pregnant 
women in Zimbabwe are HIV-positive and an estimated 15 000 children are consequently 
infected by HIV each year (United Nations Population Fund. 2010). It was recently shown 
that that even with single dose nevirapine prophylaxis, the rate of HIV MTCT is as high as 













The introduction of ART has meant that HIV/AIDS patients now survive longer compared to 
the pre-ART time, thus the long term effects of living with the HIV on target organs are only 
starting to be understood now but there are many gaps. HIV has been shown to target the 
central nervous system (CNS) in its early stages of infection (Davis et al. 1992). This is 
thought to lead to neurological complications such as motor impairments and cognitive 
deficits at a later stage (Zhou et al. 2009). An estimated 30% of HIV infected individuals and 
50% of those with AIDS have been reported to exhibit signs of neurologic disease (Heaton et 
al. 2004). A study among Americans reported that even in the presence of ART, HIV-
associated neurocognitive impairments exist in up to 40% of HIV patients with increase as 
the disease progresses (Heaton et al. 2011). Neurological impairments interfere with 
cognitively demanding activities such as work, driving, operation of machinery and 
management of medication and also increase the risk of early mortality in HIV patients 
(Heaton et al. 2004, Hinkin et al. 2004).  
The occurrence and extent of damage caused by neurological impairments and other 
HIV/AIDS related morbidities differs amongst individuals and populations. Since the early 
years of HIV/AIDS, it has been observed that disease progression varies among infected 
individuals (De Rossi et al. 1996). Some individuals may survive asymptomatically for up to 
15 years from time of infection even without ART (long term non-progressors) whilst some 
deteriorate rapidly reaching the AIDS stage within months to two years (rapid progressors)  
(Pantaleo et al. 1996). However, about 70-80% of HIV infected people are intermediate 
progressors whose immune system declines at a steady rate reaching the symptomatic stage 













In addition, a fraction of the world‟s population seems to be resistant to HIV infection as 
observed in people who remained uninfected despite repeated exposure to HIV (Fowke et al. 
1996, Tomescu et al. 2011, Kroner et al. 1994). Another study on patients with haemophilia 
A who were transfused with HIV contaminated factor VIII concentrates before the discovery 
of HIV reported that about 5% remained uninfected despite constant exposure to HIV 
(Kroner et al. 1994). These findings point to inter-individual differences that influence the 
host response to HIV exposure. Factors affecting the risk of HIV infection and/or disease 
progression include viral, immunological and host genetic variation (Langford et al. 2007). 
This study sets out to determine if inter-individual genetic variation plays a role in one‟s risk 
of HIV infection and neurocognitive function in children born to HIV-infected mothers. In 
order to understand the role of host genetics in fighting HIV, one needs to understand the 
structure and pathophysiology of HIV. 
1.2 HIV structure  
HIV is a member of the retroviridae family which are RNA viruses that require a reverse 
transcriptase enzyme to replicate (Barré-Sinoussi et al. 1983). HIV is made up of two classes, 
HIV-1 which is common worldwide and HIV-2 which is largely restricted to West Africa. 
HIV-1 has subtypes A to K, up to 49 circulatory recombinant forms (CRF) and several 
unique recombinant forms (URF). The HIV-1 subtypes exhibit distinctive geographical 
distribution across the world with subtype A predominant found in East Africa, subtype B is 
in Europe, America and Australia and subtype C which makes up >80% of HIV-1 infections 













The distribution of HIV subtypes appears to follow patterns of HIV prevalence in different 
parts of the world suggesting that host genetic variation may have shaped the distribution of 
HIV subtypes by exerting selective pressure (Taylor et al. 2008).  
The HIV genome is made up of two identical copies of positive strand RNA held together by 
hydrogen bonds (Huet et al. 1990). The HIV genome carries three structural genes named, 
group antigen (gag), polymerase (pol) and envelope (env). The three genes code for five 
major structural proteins (gp120, gp41, p24, p17 and p7) and three non-structural proteins 
namely reverse transcriptase (RT), integrase and protease which facilitate the viral life cycle 
(Vanhée-Brossollet et al. 1995). HIV also has six regulatory genes which code for proteins 
involved at various stages of its cycle in a host cell. These are; viral infectivity factor (vif), 
viral protein R (vpr), viral protein U (vpu), trans-activator of transcription (tat), negative 
factor (nef) and regulator of expression of viral proteins (rev) (Vanhée-Brossollet et al. 
1995). Despite having a 9.1 kilo base (kb) genome, HIV is highly virulent and infectious. 
HIV is transmitted from one individual to the next when infected body fluids such as semen, 
vaginal fluid and blood find their way into an uninfected person‟s system. The main modes of 
HIV transmission are sexual intercourse and mother-to-child transmission. Sharing of sharp 
objects and blood transfusion are minor contributors. This study focuses on children who 
















1.3 Mother-to-child transmission of HIV 
MTCT can occur during pregnancy (in-utero), at delivery (intrapartum) and after birth 
(postpartum). Studies have shown that in-utero HIV transmission accounts for 15-20% of the 
cases, breastfeeding 30-40% whilst approximately 50% of the events take place around 
delivery (Bryson et al. 1992, De Cock et al. 2000). In-utero HIV transmission occurs mainly 
through trans-placental passage of HIV (Backe et al. 1992). Even though the placenta forms a 
barrier that protects the developing foetus from HIV, the virus is able to penetrate through 
breaches in the barrier and/or transcytosis of intracellular HIV (Backe et al. 1992). HIV 
transmission during delivery takes place when the infant‟s skin and mucous membranes are 
exposed to infected maternal blood, amniotic fluid and vaginal secretions during passage 
through the birth canal (Perry et al., 2010). Breastfeeding forms the main mode of vertical 
HIV transmission postpartum. The risk of transmission is highest just after delivery due to the 
high viral load in colostrum (Rousseau et al., 2003).  
The risk of HIV MTCT at any of these stages depends on both maternal and foetal factors. 
Factors determining risk of HIV MTCT include clinical and immunological status of the 
mother (HIV disease stage, co-infections), viral characteristics, tissue integrity in both mother 
and child and host genetic make-up of both mother and child (Renjifo et al. 2004, Singh et al. 
2009). Co-infections such as sexually transmitted micro-organisms, malaria and tuberculosis 
in the mother increase the risk of transmitting HIV to the child (Gumbo et al. 2010, Gupta et 
al. 2011).  This study focuses on the possible effect of child genetic variation on their risk of 
being infected from an HIV-infected mother. Control of HIV MTCT is dependent on the 
correct and timely diagnosis of HIV which guides subsequent treatment during pregnancy, 













1.4 HIV Diagnosis 
Diagnosis of HIV is based on detection of the virus (virological) or antibodies produced 
against the virus (serological) in body fluids such as blood and blood products. Antibody 
detection based methods include enzyme linked immune-sorbent assay (ELISA), 
immunochromatography, and western blotting (Burke et al. 1987). Viral detection methods 
include p24 antigen test and nucleic acid amplification based tests (Sherman et al. 2005). 
HIV diagnosis using serological methods in children less than 18 months of age is difficult 
because sero-conversion is not certain at that stage due to their immature immune system 
therefore WHO recommends virological tests in infant HIV diagnosis (WHO 2010).  
Once diagnosed of HIV, patients need to be monitored on a regular basis for effective 
treatment purposes. CD4+ T-cell counts and HIV quantification are used in patient 
monitoring and initiation of ART in HIV patients. In infants, WHO recommends immediate 
initiation of ART once the child has been diagnosed (WHO 2011) as studies have shown 
better survival in children who start therapy before they develop clinical symptoms 
(Chiappini et al. 2006, Violari et al. 2008). Despite the wide use of ART in HIV treatment, 
patients still progress to AIDS at different rates indicating the role of inter-individual 

















1.5 HIV pathogenesis and host genetics 
1.5.1 HIV life cycle  
HIV can only replicate inside a living host cell because in its complex life cycle, viral 
components have to interact with host proteins to execute their roles. Since the HIV genome 
only codes for about 15 proteins, its life-cycle like all retroviruses, is highly dependent on the 
host cell machinery (Frankel et al. 1998). The main stages in HIV life cycle are attachment 
and entry, reverse transcription, integration, transcription, assembly and budding. Figure 1.2 
is an illustration of the HIV life cycle in a host cell.  
 














HIV infects the human cell by attaching its envelope glycoprotein 120 (gp120) to CD4 
receptors on host cells such as T-lymphocytes, macrophages, langerhans cells and dendritic 
cells (Orloff et al. 1991, Rosenberg et al. 1991). This attachment causes gp120 to undergo a 
structural change that results in engagement of one of the major co-receptors, CCR5 or 
CXCR4.  Gp41 an HIV transmembrane glycoprotein, then facilitates the transfer of the viral 
capsid into the host cell (McClure et al. 1988). Post-entry, the viral capsid is released into the 
cytoplasm where the outer viral lipid envelope is removed releasing the viral genome for 
reverse transcription to complementary DNA (cDNA) by viral reverse transcriptase enzyme 
(Chan et al. 1998). Once viral cDNA is made, it is combined with host proteins to form a pre-
integration complex (PIC). This complex is necessary for translocation of the nucleic acid 
material to the nucleus where it is integrated into the human DNA by enzyme DNA integrase 
(Shun et al. 2007). The integrated DNA may lie dormant or is replicated simultaneously 
when human DNA multiplies before undergoing transcription to produce viral mRNA (Pace 
et al. 2011). 
Tat is the only transcription factor encoded by HIV genome therefore human transcription 
factors are recruited to assist in the process (Calman et al. 1988). HIV protein Rev attaches to 
newly formed mRNA and shuttles it from the nucleus to the endoplasmic reticulum for 
further processing and translation (Pollard et al. 1998). Structural proteins encoded by viral 
genome such as Gag and Env bind to the viral RNA (Pollard et al. 1998). At the cell 
membrane, gp41 and gp120 are anchored into the membrane whilst the viral genome and 
proteins are assembled before a virion buds off, matures and goes on to infect other cells 
where they will undergo the same cycle in a repeated process (Gabuzda et al. 1992). Since 
HIV life cycle is heavily dependent on its interaction with host proteins, polymorphism in 













1.5.2 HIV/AIDS restriction genes 
Host genes whose variation influences course of HIV infection and disease are known as 
AIDS restriction genes (ARGs) (O'Brien et al. 2004). Some ARGs directly interfere with the 
HIV life cycle in a host cell whilst others may affect the host immune system. ARGs can be 
categorised into gene encoding the following; (1) chemokine receptors (e.g. CCR5, CCR2 
and CX3CR1), (2) chemokines (e.g. stromal cell derived factor, SDF1; regulated on 
activation normal T-cell expressed and secreted, RANTES and monocyte chemoattractant 
protein, MCP-1) and (3) innate immune factors (e.g. apolipoprotein B mRNA-editing 
enzyme-catalytic polypeptide-like 3G, APOBEC3G; tripartite motif 5α, TRIM5α and 
mannose binding lectin, MBL2) (Singh et al. 2009, Hutcheson et al. 2008).  
An example of chemokine receptor polymorphism is a 32 base pair deletion in the human 
CCR5 receptor gene (CCR5 ∆32) which leads to production of an aberrant protein that 
reduces HIV binding affinity to the receptor, thus, reducing chances of HIV infecting the host 
cell (Carrington et al. 1997). Chemokines on the other end, compete with HIV for co-
receptor binding, thus, host polymorphisms that increase chemokine expression, for example, 
that of the RANTES and SDF1 genes may confer a protective advantage against HIV whilst 
the opposite is true (An et al. 2002, Amara et al. 2010). In addition to SNPs, gene copy 
number variation (CNV) in a chemokine gene CCL3L1 has also been reported to influence 
susceptibility to HIV/AIDS through the competitive block of the chemokine‟s receptor CCR5 
(Gonzalez et al. 2005). CCL3L1 CNV however, does not form part of our current study. 
Variation in genes that encode immunological factors may affect HIV infection by 
differential regulation of proteins involved in mounting a response against HIV such as 













For example, low expression and poor oligomerisation of the mannose binding lectin (MBL) 
due to polymorphism in the gene encoding the protein (MBL2) have been linked with 
increased susceptibility to HIV infection and rapid disease progression in HIV patients 
(Boniotto et al. 2000, Mangano et al. 2008).  The focus of this study is narrowed to two 
chemokine receptor genes (CCR2 and CX3CR1), two chemokine genes (RANTES and SDF1) 
and two innate immune factor genes (APOBEC3G and MBL2). The study therefore was 
aimed at describing the distribution of their allelic variants in children born to HIV-infected 
mothers and their possible role in HIV infection and neurocognitive function. Figure 1.3 





Figure 1.3: Schematic showing the viral restriction factors investigated in this study and 














1.5.3 Distribution of HIV restriction genetic variants 
There are several genetic variants that have been linked with differential HIV-related 
outcomes and their distribution varies amongst populations. This has made it difficult to 
come to a general consensus of their role in HIV pathogenesis (Martinson et al. 2000). The 
distribution of some genetic variants show trends across geographical boundaries suggesting 
that environmental factors could have influenced the polymorphism before HIV was 
discovered. For example, the CCR5 ∆32 is prevalent in up to 15% of Caucasians but has not 
been found in African populations (Lucotte et al. 1998). In Europe where CCR5 ∆32 allele is 
most common, it exhibits a decreasing trend in frequency from the North to South and West 
to East of the continent (Faure et al. 2008). Some authors have suggested that epidemics such 
as the bubonic plague in 1346-52 could have caused the deletion (Stephens et al. 1998) but 
others have argued that the distribution of CCR5 ∆32 allele does not follow that of the plague 
(Cohn Jr et al. 2006).  
Other variants such as CCR2 190A and SDF1-3′A do not show such defined trends among 
world populations and their frequencies tend to differ even among closely related populations 
(Ma et al. 2005, Qian et al. 2008). For example, the frequencies of both CCR2 190A and 
SDF1 801A alleles range from an estimated 1% to 30% in East Asian populations (Su et al. 
1999) whist CCR2 190A allele frequencies range from 10-30% in seven Cameroonian tribes 
(Ma et al. 2005). Given the varied distribution of ARGs, it is important to investigate their 
frequency in all populations so that we may be able to approximate how they may be 
contributing to the HIV burden. The information may be useful in predicting HIV risk and 














1.6 HIV disease progression 
Despite the influence of host genetic variation in HIV life cycle and host immune 
mechanisms, HIV generally follows defined stages in its progression from infection to AIDS 
and subsequently death (Figure 1.4). Two to four weeks after infection, an infected person 
goes through the acute infection stage when HIV replication is very high. HIV attacks and 
kills CD4+ T-cells at a fast rate and the infected person may experience several illnesses 
including “flu like” symptoms (Cohen et al. 2011). The innate and CD8+ T-cell mediated 
immune factors mount a response against HIV that reduces viraemia to set point and allows 
CD4+ T-cells to recuperate (Deeks et al. 2004). This is followed by an asymptomatic HIV 
latency stage when the body is able to control HIV even though the virus still multiplies at a 
slow rate and CD4+ cell counts fall gradually. This period may last for several years and the 
length of time differs from one individual to the next which is suggestive of genetic variation 
influence (Siliciano et al. 2011).  
 
Figure 1.4: Stages in HIV disease progression. Host genetic variation in HIV/AIDS restriction genes 













After several years of latency, one may progress to an AIDS stage. AIDS is marked by severe 
reduction of CD4+ T-cell count, high viraemia and opportunistic infections. The course of 
HIV disease progression in children is different from that in adults. HIV tends to generally 
progress faster with more serious effects in infants because of their immature immune system 
(Kuhn et al. 1999). Accelerated HIV disease could also be because children born to HIV 
infected mothers tend to acquire a virus with history of resistance (Tiemessen et al. 2006). 
HIV strains resistant to the maternal immune system are more efficiently transmitted from 
mother to child compared to well-controlled ones (Dickover et al. 2001).  
HIV disease progression is very rapid during the first year of life and about 10-15% of the 
infected children are likely to die before by their first birthday (Spira et al. 1999, Pliner et al. 
1998). The children exhibit a high viral loads which decrease at a slower rate compared to 
adults (Frederick et al. 1994). Contrary to adult immune systems where cytotoxic T 
lymphocyte responses reduce viraemia, infant immune responses produce virus specific 
CD8+ cells but they do not seem to reduce the amount of circulating virus (Lohman et al. 
2005). Because of the poor ability to control HIV, HIV-infected children become a target for 
a wide spectrum of opportunistic infections. They experience recurrent bacterial infections, 
pneumonia, meningitis, viral respiratory infections to mention a few (Owor et al. 2004). They 
may show stunted growth, walking difficulties, poor social development and a range of 
neurological complications (McAthur et al. 2005). We therefore aim to determine if genetic 
variation has an effect on markers of disease progression such as CD4+ T-cell count and 















1.7 Pathogenesis of HIV-associated neurocognitive disorders  
HIV-associated neurocognitive disorders have been observed since the early stages of HIV 
(Grant et al. 1987, Mayeux et al. 1993). During the middle 1990‟s, an estimated 60% of HIV-
infected patients had neuro-pathological conditions detected during post-mortem (Levy 
1997). Ten years later, 15% of patients still developed HIV-associated dementia (HAD) 
whilst from 30-60% had the less severe forms (Gendelman et al. 2005; McArthur et al. 
2004). These neurological complications are more aggravated in children in whom 50% of 
the untreated develop HAD and their intellectual ability is heavily compromised (González-
Scarano et al. 2005).  
In affected children problems include inefficient problem solving, poor planning and lack of 
general organisation. More complex manifestations involving visual-spatial processing, 
impaired fine motor skills as shown by poor arithmetic skills, difficulties carrying out daily 
activities such as dressing and poor handwriting develop with progression in the condition 
(Bisiacchi et al. 2000). With time, psychiatric complications can be observed in the children 
characterised by depression, delirium, anxiety, disorders, attention deficit-hyperactivity 
disorder (Brouwers et al. 1995, Krebs et al. 2000). The use of ART has improved the clinical 
outcome and reduced the prevalence of the serious forms of HIV-associated neurocognitive 
deficits but mild forms are still rampant with persistent impairment to the patients   (Cysique 
et al. 2009). The first step in HIV neuropathogenesis involves HIV crossing the blood brain 
barrier (BBB) into the CNS. 
The BBB is fashioned to provide biologic, physiological and immunological separation 
between the CNS and the rest of the circulation (Strazza et al. 2011). HIV exploits host 













Garcia et al. 2005). The process begins with HIV infecting circulating monocytes where it 
remains latent. Whilst inside the monocytes, the virus enters the CNS during immune-
surveillance and replacement of perivascular macrophages (Williams et al. 1990, Garcia-
Garcia et al. 2005). This process is regulated by the secretion of chemokines such as 
macrophage inflammatory protein 1, monocyte chemoattractant protein 1 and RANTES. 
Other mechanisms of entry include macropinocytosis (Liu et al. 2002) and adoptive 
endocytosis mechanism mediated by gp120 (Banks et al. 2001).  
Presence of HIV in the CNS introduces viral proteins such as gp120, Tat and Nef which 
increase secretion of chemokines, chemokine receptors, cytokines, nitric oxide and 
prostaglandins (Annunziata 2003, Strazza et al. 2011). Under normal physiological 
conditions, selected chemokines are expressed in the brain (Levine et al. 2009). These 
chemokines aid in leukocyte trafficking, cytokine activation, cell adhesion and other 
immunological roles. In the presence of HIV, this controlled environment is disturbed and 
non-specific chemokine expression is increased. This results in general inflammation of the 
organ and disruption of tight junctions of the BBB allowing more rapid entry of the HIV 
infected macrophages into the brain (Strazza et al. 2011).  
Although disruption of the BBB and entry of the virus occurs early in infection, at that point 
it doesn‟t cause damage as HIV does not infect neurons and its penetration of endothelial 
cells occurs without productive infection (Liu et al. 2002). The fact that neurocognitive 
impairments mainly occur in the later stage of infection suggests that neurocognitive 
impairment may be a factor of disease progression (Liu et al. 2002). HIV-infected individuals 
exhibit inter-individual differences in the severity of neurocognitive deficits strongly pointing 













In a different dynamic, Bagenda et al., (2006) have reported neurocognitive impairment 
among HIV-uninfected children suggesting that other etiological factors besides HIV/AIDS 
are important in neurocognitive deficits. The possible effects of human genetic variation on 
neurocognitive function are not well described. A study among American children reported 
an accelerated tendency to neurocognitive impairment among HIV-infected individuals 
carrying the chemokine gene variant SDF1-3′ A/A compared to the SDF1-3′G/G and G/A 
genotypes but did not observe any relationship with polymorphisms in genes encoding 
chemokine receptors CCR5 and CCR2 (Singh et al. 2003). However, another study reported 
better neurodevelopmental outcomes among children with the mutant CCR5 genotypes 
compared to the wild-types and any of the CCR2 genotypes (Llorente et al. 2006).  
In addition to variations in chemokines and chemokine receptors, polymorphism in a human 
gene encoding the MBL protein called MBL2 have been implicated in HIV-associated 
neurocognitive impairments (Singh et al. 2008, Spector et al. 2010). Here, the MBL2 variants 
associated with poor oligomerisation of MBL polypeptides to form functional units tend to 
present a higher risk of one developing neurocognitive impairments. This observation 
highlights the importance of the innate immune system in neuropathogenesis especially in 
HIV-infected individuals who are constantly faced with opportunistic infections that target 
the central nervous system. Several other studies have reported a number of SNPs involved 
in several pathways to influence the outcomes of HAD/HAND (Gonzalez et al. 2002, 
Pemberton et al. 2008, Bol et al. 2012). However, the first genome wide associated study 
(GWAS) on neurocognitive impairment hosting 1287 participants has dismissed most of the 
associations (Levine et al. 2012). Not much work has been reported among African 
populations therefore this study attempts to elucidate the correlation between host genetic 













1.8 Chemokines and their receptors 
Chemokines are a type of cytokines made up of structurally related, small and highly basic 
proteins (Zlotnik et al. 2000). Chemokines and their receptors direct cells towards locations 
where they carry out specific functions in a process called leukocyte trafficking (Mahalingam 
et al. 2001). There are about 53 chemokines that interact with over 23 receptors in a 
promiscuous system where a chemokine may bind to more than one receptor and vice versa  
(Bonavia et al. 2003). In summary, chemokines can be grouped into four classes CC, XC, 
CX3C and CXC according to the spacing of cysteine residues on conserved sequences of the 
N-terminal region that influence formation of secondary structures (Murphy et al. 2000). 
Table 1.1 shows the classification of chemokines and their receptors with a few examples 
cited. 
Table 1.1: Classification of chemokines and chemokine receptors 
Class Chemokine receptor Chemokine  
C XCR1 XCL1 (Lymphotactin) 
C-C CCR2 
CCR5 
CCL2 (MCP-1), CCL8 (MCP-2) 
CCL5 (RANTES), MCP-2, CCL3 (MIP-1α) 
C-X-C CXCR4 
CXCR1 
Stromal cell-derived factor (SDF-1) 
Interleukin 8, CXCL6 (GCP-2) 
C-X3-C CX3CR1 CX3CL1 (Fractalkine) 
Key: MCP- monocyte chemoattractant protein, RANTES- regulated on activation, normal T-cell excreted and 
secreted, MIP- macrophage inflammatory protein, GCP- granulocyte chemotactic protein.                              















Chemokines carry out a wide range of functions by binding to their G protein-coupled 
receptors (GPCR) on cells. When a chemokine binds to its receptor, a protein attached to the 
receptor is activated and released to initiate a cascade of reactions that involves 
phopholipases and change in cytosolic calcium (Bokoch 1995). The eventual result of the 
chain is activation of several transcription factors such as CREB and STAT which increase 
gene expression and proliferation (Bokoch 1995, Kuang et al. 1996). Chemokines are 
actively involved in the immune system where they modulate both the innate and adaptive 
immune processes such as primary leukocyte trafficking, immune surveillance and 
inflammatory cell recruitment (Bajetto et al. 2001). Chemokines are also involved in 
embryonic development, wound healing, angiogenesis, leukocyte infiltration, metastasis of 
tumours and apoptosis (Belperio et al. 2000, Ishida et al. 2008, Lazennec et al. 2010). 
In addition to the above mentioned functions, chemokine receptors also act as co-receptors to 
HIV e.g. CCR5, CXCR4 and CCR2 (Deng et al. 1996, Feng et al. 1996). This led to 
investigation into the role of these co-receptors in HIV disease mechanisms. Sequencing of 
genes encoding CCR5, CCR2, CX3CR1 and other minor co-receptors has shown several 
polymorphisms that seem to affect HIV infection and disease progression. Scientists have 
invested a lot of effort in describing the distribution of the polymorphisms in different 
populations across the world but Africans remain understudied. Zimbabwe is no exception 
and to our knowledge, this study will be the first to describe most of the variations in 
chemokine/chemokine receptor genes among Zimbabweans. The focus of this study is on 
polymorphism in genes encoding two chemokine receptors (CX3CR1 and CCR2), two 














1.8.1 C-X3-C chemokine receptor type 1 (CX3CR1) 
Chemokine receptor CX3CR1 was first reported in 1997 (Imai et al. 1997) as a high-affinity 
ligand for the chemokine of CX3C motif called fractalkine (CX3CL1) (Bazan et al. 1997). 
The receptor-ligand combination, CX3CR1-fractalkine facilitates leukocyte trafficking as 
cells carrying the CX3CR1 receptor migrate towards regions of high fractalkine expression. 
CX3CR1 is highly expressed on monocytes, natural killer cells and a selection of T-
lymphocytes and therefore plays a part in their recruitment during immune responses      
(Imai et al. 1997, Nishimura et al. 2002). CX3CR1 is also expressed in astrocytes and glial 
cells of the CNS where it is involved in neuronal activity (Nishiyori et al. 1998, Meucci et al. 
2000). In addition to leukocyte trafficking, CX3CR1 also acts as an HIV co-receptor 
(Combadiere et al. 1998). Expression of its ligand fractalkine has been reported to differ 
between groups of HIV-infected and HIV-uninfected individuals suggesting that CX3CR1 
and fractalkine have an active role in immunity against HIV (Foussat et al. 2001). Fractalkine 
is also highly expressed in the brain of HIV infected patients and may be a culprit in HAD 
(Cotter et al. 2002).  
CX3CR1 is encoded by an 18kb long gene located with 4 other chemokine receptor genes on 
chromosome 3 (Maho et al. 1999). Two non-synonymous SNPs, CX3CR1 745G>A (V249I) 
and 839T>C (T280M) have been reported in the sixth and seven transmembrane domains of 
CX3CR1 protein (Faure et al. 2000). The resulting amino acid substitutions have been 
reported to reduce the binding of CX3CR1 to its cognate ligand fractalkine                    
(Faure et al. 2000). Alleles 745A and 839T were reported to be in complete linkage 













The resulting 745-839 (A-T) haplotype is associated with decreased monocyte binding and 
poor fractalkine-dependant cell to cell adhesion (McDermott et al. 2003). Individuals 
carrying the homozygous 839T/T genotype therefore exhibit reduced fractalkine binding and 
fractalkine induced leukocyte chemotaxis (McDermott et al. 2003). The reduced potency of 
CX3CR1 in leukocyte trafficking negatively affects its ability to activate the immune system. 
This offers a possible explanation why the A-T haplotype was reported to be associated with 
accelerated HIV/AIDS disease progression in one of the earliest studies on CX3CR1 variation 
and HIV (Faure et al. 2000). 
Subsequent studies have reported conflicting findings on the effect of CX3CR1 745A and 
839T alleles on HIV/AIDS disease progression. Some reported the 745A and 839T alleles to 
be associated with faster HIV disease progression compared to 745G and 839C alleles, 
respectively (Faure et al. 2003, Brumme et al. 2003, Singh et al. 2005). Others have not 
found any significant association (Hendel et al. 2001, Kwa et al. 2003, Suresh et al. 2006) 
whilst one study demonstrated association between the alleles (745A and 839T) and long 
term non-progression in HIV-infected patients (Vidal et al. 2005). However, most of these 
studies were carried out in adult populations and not much has been done in paediatric 
populations especially in sub-Saharan Africa.  
One of few studies done in children was a multicentre study in the USA which showed that 
children with 745A/A genotype experienced more rapid disease progression and a trend 
towards neurocognitive impairment compared to those with the 745G/G genotype         
(Singh et al. 2005). Another study involving Malawian, South African and Ugandan pregnant 
women, some treatment naive and others on zidovudine prophylaxis, did not find any 













There is no general consensus on the effect of CX3CR1 polymorphism on risk of HIV 
infection or disease progression. In addition to the CX3CR1 gene, polymorphism in another 
chemokine receptor gene, CCR2 was also investigated.  
1.8.2 C-C Chemokine receptor type 2 (CCR2) 
CCR2 is a seven transmembrane chemokine receptor found on several cells including 
monocytes, myeloid precursor cells and activated T-cells (Myers et al. 1995).  CCR2 is 
involved in several functions including migration of monocytes from the bone marrow where 
they are made to peripheral circulation during inflammation, bone homeostasis and 
maintenance of physiologically correct chemokines levels through scavenging of excess 
chemokines (Palframan et al. 2001, Cardona et al. 2008, Binder et al. 2009).  
In addition to its physiological roles, CCR2 is also a minor HIV co-receptor and has been 
implicated in HIV-associated dementia and other neurological disorders such as Alzheimer‟s 
disease and multiple sclerosis (Vos et al. 2000, Gonzalez et al. 2002). The CCR2 is a 7kb 
gene on chromosome 3p21 (Daugherty et al. 1997). A 190G>A polymorphism in the protein 
coding region of CCR2 gene results in a valine to isoleucine change at amino acid 64 of the 
receptor (V64I) (Charo et al. 1994, Smith et al. 1997). The CCR2 190>A has been reported in 
most populations and is one of the most widely studied HIV/AIDS restriction genetic 
variants (Martinson et al. 2000). The CCR2 190A allele enhances gene expression and 
prolonged half-life of its CCR2A isoform (Nakayama et al. 2004). The 64I containing variant 
of CCR2 receptor dimerises with CXCR4 receptor after binding of its ligand whereas the 
64Vvariant has reduced affinity. This reduces the amount of CXCR4 available to bind the X4 
HIV strain on the cell surface among CCR2 190A carriers, thus conferring a protective 













A study among Cameroonians reported a protective effect against HIV infection in males 
carrying the CCR2 190A allele compared to the 190G allele. However this association was 
not observed in females where other factors such as multiple pregnancies and other maternal 
stressors may have masked the genetic effect (Ma et al. 2005). The protective effect of the 
CCR2 190A variant is further supported by reports that CCR2-CCR5 haplotypes containing 
the 190A allele were more frequent in HIV-exposed but uninfected adults compared to the 
HIV-infected among Thais and Zambians (Malhotra et al. 2011, Wichukchinda et al. 2008). 
However, some studies have failed to observe any association between CCR2 190G>A 
variants and HIV transmission (Smith et al. 1997, Alagarasu et al. 2009). The bulk of studies 
have been done on adult populations but the effect of CCR2 190G>A variants on HIV 
transmission in children is not well described.  
Some of the few studies involving children reported a protective effect against HIV MTCT in 
children carrying the 190A allele compared to those with the 190G allele (Mangano et al. 
2000, Mabuka et al. 2009). In contrast, a multicentre study involving Malawians, South 
Africans and Ugandans reported an increased risk of HIV MTCT in children with the 
homozygous 190A/A genotype compared to 190G containing genotypes (Singh et al. 2008). 
Our study aims to elucidate the effect of CCR2 190G>A variation on the risk of HIV 
infection among who are perinatally exposed to HIV. 
 In individuals already infected by HIV, several studies have suggested a better prognosis in 
HIV/AIDS patients carrying the CCR2 190A variant (Smith et al. 1997, Mangano et al. 2000, 
Kostrikis et al. 1998, Kostrikis et al. 1998, Vieira et al. 2011, Vieira et al. 2011, Mulherin et 













Moreover HIV/AIDS, the 190G>A variants have been shown to influence the outcome of 
several other clinical conditions such as cancer (Chatterjee et al. 2010, Chen et al. 2011), 
preeclampsia (Agachan et al. 2010), myocardial infarction (Karaali et al. 2010) and 
atherosclerosis (Nyquist et al. 2009). This can be attributed to the receptor‟s wide spectrum 
of roles in the immune system through activation of immune cells. In addition to CX3CR1 
and CCR2 receptor genes, the study also investigated genetic variation in two chemokine 
genes SDF1 and RANTES. SDF1 and RANTES are the natural ligands of the two main HIV 
co-receptors CXCR4 and CCR5 respectively (Deng et al. 1996). 
1.8.3 Stromal cell derived factor 1 (SDF1) 
Stromal cell derived factor (SDF) is a CXC chemokine originally described as a secreted 
product of bone marrow stromal cell line (Tashiro et al. 1993). SDF is encoded by the 
CXCL12 (SDF1) gene.  The SDF1 gene is located on chromosome 10 spanning a 17kb 
region. SDF1 is chemoattractant involved in leukocyte trafficking of several cell lines 
including T-cells, monocytes, pre-B cells, dendritic cells, and haematopoietic progenitor cells 
(Sozzani et al. 1997, Möhle et al. 1998, Bleul et al. 1996). The SDF1-CXCR4 combination is 
vital for developmental processes such as cardiogenesis, brain development and guidance of 
primordial germ cell (Tachibana et al. 1998, Ara et al. 2003). Furthermore, SDF1 is also 
active in CNS physiology with phylogenetic studies showing that the CXC family has 
ancestral roles in the CNS opposed to the immune system (Huising et al. 2003, Guyon et al. 
2007). Both CXCR4 and SDF-1 are constitutively expressed by glial and neuronal cells in 
the CNS (Bonavia et al. 2003, Bajetto et al. 2001) with co-distribution of the pair in a number 













Despite the multiple role of SDF1, this study focused on the how its genetic variation might 
affect HIV infection and neurocognitive development. The chemokine SDF1 inhibits 
infection of the host cell by HIV through competitive binding of the HIV co-receptor CXCR4 
(Oberlin et al. 1996, Yuan et al. 2000). SDF1 has also been implicated in HIV-HAND due to 
its active role in CNS physiology. Investigations on variation in the SDF1 gene led to the 
discovery of a G>A change at position 801 in the 3′ untranslated (3′-UTR) region of the gene 
(SDF1 801G>A; SDF1-3′G>A) (Oberlin et al. 1996). The SDF1 801G>A SNP has been 
implicated in differential HIV transmission and disease progression. This is because the 
801A allele up-regulates the synthesis of the SDF1 protein by stabilising the mRNA allowing 
for more competitive binding against HIV (Winkler et al. 1998, Shirozu et al. 1995).  
Reports on the role of SDF1 variants in HIV infection and disease progression are 
conflicting. One of the earliest studies reported slower disease progression in individuals 
carrying the SDF1 801A allele compared to those with the 801G variant                     
(Winkler et al. 1998). This observation was disputed by several subsequent studies that found 
the 801A to be associated with accelerated progression from infection to AIDS            
(Amara et al. 2010, Mummidi et al. 1998, van Rij et al. 1998)  whilst others have not found 
any association (Watanabe et al. 2003, Reiche et al. 2006).The relationship between 801G>A 
variants and either HIV infection or disease progression in African and paediatric populations 
is not well described. Among the Xhosa speaking people of South Africa, the SDF1 801A 
was reported to increase risk of HIV infection in adults (Petersen et al. 2005). In one of the 
few African studies involving children Singh et al. (2003) reported rapid disease progression 
in individuals with homozygous SDF1 801A/A compared to 801G/G and 801G/A carrying 













Despite SDF1‟s active involvement in CNS pathophysiology, the effect of variation in its 
encoding gene on HIV associated neurocognitive impairments is not well described, thus, its 
inclusion in this study. Whilst SDF1 binds to HIV co-receptor CXCR4, another chemokine 
RANTES binds to the other main HIV co-receptor, CCR5.  
1.8.4 Regulated on Activation Normal T-cell Expressed and Secreted  
 Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES); CCL3L1 and 
Monocyte Inflammatory Proteins, MIP-1α (CCL3)  and MIP-1β (CCL4) encoded by host 
genes CCL5 (RANTES), CCL3L1, CCL3 and CCL4, respectively, are ligands to the 
chemokine receptor and HIV R5 co-receptor CCR5 (Table 1.1) (Deng et al. 1996, Cocchi et 
al. 1995, Torre et al. 2000, Gonzalez et al., 2005). RANTES, CCL3, CCL4 and CCL3L1 
exhibit anti-HIV activities through competitive block of CCR5. Of the genes encoding the 
four chemokines, RANTES is the most studied and SNPs that influence HIV outcomes show 
a worldwide distribution, thus was selected t  form part of this study. 
 RANTES also inhibits HIV infection by reducing cell surface CCR5 levels (Mack et al. 
1998). The discovery of the interaction between RANTES and CCR5 presented a potential 
therapeutic strategy against HIV. The strategy is based on co-receptor blockage and has led 
to the first CCR5 inhibitor drug called maraviroc (Fätkenheuer et al., 2005). CCR5 
antagonism has also been exploited in the “cure” of the Berlin patient with HIV and acute 
myeloid leukaemia in whom CCR5 negative stem cells were successfully used to clear both 














Primarily RANTES is a chemoattractant for a variety of cell types including monocytes, 
natural killer cells, memory T cells, eosinophils and dendritic cells (Loetscher et al. 1994, 
Schall et al. 1990, Rot et al. 1992). RANTES plays an important role in immune regulation 
against respiratory viral infections such as the common influenza and respiratory synctia 
virus (Hao et al. 2008, Culley et al. 2006). It was also shown that in RANTES deficient mice, 
virus-specific CD8+ T cells had poor cytokine production with reduced cytotoxic ability 
(Crawford et al. 2011). In the CNS, RANTES is produced in astrocytes and up-regulated in 
HIV infection. This elevation of RANTES in the CNS has been reported to be associated 
with SIV encephalitis (Barnes et al. 1996). Execution of RANTES function depends on how 
much of the chemokine is available in the circulation for certain pathways. 
RANTES levels in circulation show inter-individuals differences and in the context of 
HIV/AIDS, different levels of RANTES could result in differences in inhibition of HIV-
CCR5 binding and therefore risk of infection or disease progression. The differences in 
RANTES levels can be attributed to variation in the RANTES gene, thus, RANTES 
polymorphisms have been linked with HIV transmission and/or disease progression.  Three 
RANTES SNPs namely -403G>A and -28C>G in the promoter region and In1.1T>C in intron 
1 have been reported to affect differential expression and protein levels of RANTES         
(An et al. 2002, Bleul et al. 1996). The -403A and -28G alleles have been reported to up-
regulate the expression of RANTES (Liu et al. 1999, Nickel et al. 2000). Increased expression 
would mean that more chemokines are available for blocking of HIV binding to CCR5 co-
receptor, thus, protection against HIV infection and disease progression. On the contrary, 
reduction of RANTES expression would result in more CCR5 being left available for HIV 













Reports on association studies between RANTES gene variants and HIV disease progression 
are conflicting. Several studies have reported slow disease progression in individuals 
carrying the -403A and/or -28G alleles (Liu et al. 1999, Koizumi et al. 2007, McDermott et 
al. 2000) whilst others have not found any association (Vidal et al. 2006). Studies on the 
effect of RANTES variants on risk of HIV infection have also reported conflicting findings 
(McDermott et al. 2000, Rathore et al. 2008, Katz et al. 2010, Ahlenstiel et al. 2005, Liu et 
al. 2004). RANTES -403G>A and -28C>G variants have also been implicated in 
susceptibility to other conditions such as hepatitis B and C, asthma (Muro et al. 2008) and 
myocardial infarction (Irina P et al. 2011). A study among Tunisians reported that the -
28G/G genotype was significantly associated with increased risk of pulmonary TB infection 
whilst -403G allele increased chances of extra pulmonary TB (Ben-Selma et al. 2011). 
Contrary to the increased expression associated with the two promoter SNPs, RANTES 
In1.1C allele affects the binding of nuclear protein to its regulatory sequence resulting in 
down-regulation of RANTES expression (An et al. 2002). The In1.1C allele has been linked 
with accelerated disease progression in HIV/AIDS patients in several studies (An et al. 2002, 
Wichukchinda et al. 2006, Gonzalez et al. 2001). A study among Indians reported the In1.1T 
allele to be a risk factor for HIV transmission whilst the In1.1C allele was associated with 
accelerated HIV disease progression. Other studies have failed to observe any association 
between the In1.1T>C variants and neither disease progression nor HIV transmission 
(Koizumi et al. 2007, Katz et al. 2010).  
There is limited information on RANTES SNPs in African population. A study among 
Ugandans reported longer survival among individuals carrying the homozygous In1.1C/C 













This study aimed to investigate the distribution of RANTES -403G>A and In1.1T>C variants 
in Zimbabwean population and how they might be associated with HIV infection and 
neurocognitive status. Even though chemokines and chemokine receptors are involved in 
HIV attachment to the host cell during infection, they are basically part of the antiviral innate 
immune system. The innate immune system is a vital player in HIV control and pathogenesis. 
1.9 Innate immune system 
The immune system forms the body‟s line of defence against infections and disease       
(Lynn et al. 2010). The immune system may be broadly classified into anatomical and 
physiological barriers, innate and adaptive immune systems. The barriers physically keep 
pathogens out of the body while the adaptive immune system is an antigen recognition-
dependent, specific response mounted against a specific pathogen by activating monoclonal 
production of specific antibodies by B-cells or effector T cells (Iwasaki et al. 2010, Turvey et 
al. 2010).  
The innate arm of the immune system is a non-specific defence line that uses a spectrum of 
pattern recognition receptors to detect pathogen-associated molecular patterns on micro-
organism (Carrington et al. 2012). The pattern recognition results in activation of 
inflammatory pathways involving cells such as macrophages, dendritic cells, mast cells, 
neutrophils and natural killer cells (Turvey et al. 2010). Non cellular pathways involved in 
the innate immune system include; lipopolysaccharide binding, C reactive protein (CRP) and 
collectins (Turvey et al. 2010). Mannose binding lectin (MBL) is part of the collectins 
(Holmskov et al. 1994). Other innate immune factors act intracellularly by targeting 













An example is the APOBEC family of cytidine deaminases which acts through recognition of 
double stranded RNA of invading pathogens (Bishop et al. 2004).  
In HIV infection, the body only manages to mount a specific immune response some weeks 
after infection leaving the innate immune system to face the virus during the early stages of 
infection. Thus, the innate immune system is the major determinant of the viral set-point. The 
viral set point in turn determines the rate of disease progression (Pantaleo et al. 1996). The 
current study investigated variation in genes encoding two innate immune factors, mannose 
binding lectin (MBL2) and apolipoprotein B m-RNA enzyme-editing catalytic polypeptide-
like 3G (APOBEC3G) and their possible role in HIV infection and neurocognitive function. 
1.9.1 Apolipoprotein B mRNA-editing catalytic polypeptide like-3G  
Apolipoprotein B mRNA-editing catalytic polypeptide like-3G (APOBEC3G/APOBEC3G) 
belongs to the APOBEC family of antiviral cytidine deaminases (Bishop et al. 2004). The 
antiviral properties of APOBEC are affected by presence of HIV regulatory protein Vif 
which is potent to viral infectivity (Sheehy et al. 2002). Early studies reported Vif to be 
present in selected cell lines called “permissive” cells where HIV is able to proliferate but 
absent in “non-permissive” where the virus can‟t replicate (Gabuzda et al. 1992,                   
von Schwedler et al. 1993). The discovery of these different cell types led to the hunt for host 
genes that were differentially expressed in these two sets of cells. It was then demonstrated 
that the APOBEC3G gene expresses antiviral function which are inhibited by Vif        
(Sheehy et al. 2002). It is now agreed that in the absence of the Vif, APOBEC3G protein is 













When the virion infects another cell, the APOBEC3G deaminate cytidine to uracil (C>U) on 
the viral minus DNA strand during reverse transcription resulting in G>A mutation in the 
complementary coding strand (Zhang et al. 2003, Lecossier et al. 2003).This is commonly 
known as G>A hypermutation. The G>A hypermutation cripples HIV infectivity by 
introducing multiple stop codons in the HIV genome (Zhang et al. 2003, Lecossier et al. 
2003). It has been reported that the 5′-CCCA-3′ sequence on the viral minus strand is a „hot 
spot for cytidine deamination (Bishop et al. 2004, Yu et al. 2004). Mutation of this sequence 
leads to the complementary 5′-TGGG-3′ changing to 5′-TAGG-3′ which translates from a 
tryptophan codon to a stop codon (TAG). Other mechanisms of APOBEC3G antiviral action 
include inhibition of viral DNA synthesis by hindering the translocation of reverse 
transcriptase along the RNA template (Malim 2009).   
The APOBEC3G protein is encoded by a 12.7kb gene on chromosome 22. A study by An et 
al. (2004) reported seven SNPs in the APOBEC3G gene, three in the promoter region, two in 
exons and two in introns. APOBEC3G 557A>G (H186R) in exon 4 is the most studied SNP 
on the gene (An et al. 2004). The APOBEC3G 557G/G genotype has been linked to 
accelerated HIV disease progression in adults of African origin but not in Caucasians        
(An et al. 2004).  This observation was supported by later studies that also reported 
accelerated HIV disease in 557G allele carrying individuals compared to those who had the 
557A allele (Do et al. 2005, Reddy et al. 2010). Most studies have failed to observe 
association between any of the APOBEC3G variants and HIV transmission (An et al. 2004, 
Do et al. 2005, Reddy et al. 2010, Valcke et al. 2006). Cho et al. (2006) attempted to 
elucidate the relationship between APOBEC3G expression and disease progression using 













Contrary to this, a study measuring mRNA levels in human cells from different groups of 
HIV-positive people reported that mRNA abundance followed the order; long term non-
progressors>HIV uninfected> progressors. APOBEC3G mRNA abundance correlated with 
CD4+ T-cell counts and inversely with viral loads (Jin et al. 2007). These observations 
suggest that increased APOBEC3G expression may slow the progression of disease in HIV 
infected individuals. 
This study investigated polymorphism at five loci (SNPs) in the APOBEC3G gene; two in the 
promoter (-571G>C and -90C>G), one in exon 4 (557A>G) and the two in introns    
(197T>C and 199C>G) to determine their baseline frequencies and possible association with 
HIV infection and neurocognitive development. Whilst APOBEC3G acts through recognition 
of double stranded viral RNA, other innate immune antiviral factors act on virus through 
recognition of surface patterns such polysaccharide chains for example, mannose binding 
lectin which also formed part of this study. 
1.9.2 Mannose Binding Lectin (MBL) 
Collectins are a family of soluble mammalian pattern recognition receptors that contain a C-
type lectin attached to a collagen-like domain (Holmskov et al. 1994). Collectins are key 
players in the innate immune system where they kill invading organisms by recognising 
pathogen-associated molecular patterns before triggering a wide spectrum of microbial 
clearance mechanisms such as aggregation, complement activation and phagocytosis 
(Holmskov et al. 1994, Turner 1996). Mannose binding lectin (MBL) is a member of the 
collectins family that is encoded by the MBL2 gene. MBL has affinity for a range of 













By binding polysaccharide chains on pathogen surfaces, MBL activates the lectin pathway of 
the complement system to kill invading micro-organism (Holmskov et al. 1994). The 
complement system has three activation pathways (Figure 1.5) which are (1) classical which 
is initiated by antibodies binding target antigens, (2) alternative pathway which is capable of 
auto-activation through a spontaneous „tick over‟ of the C3 protein when it binds to a 
microbe and (3) the lectin pathway which involves MBL and ficolins (Endo et al. 2006). 
MBL binds to carbohydrates on the surface of a micro-organism in a process that activates 
MBL-associated serine proteases (MASPs) to cleave the C4 protein of the complement 
system (Matsushita et al. 2000). Cleavage of C4 results in formation of the C3 convertase, 
C4bC2a (for the classical and lectin pathways). The C3 convertase stage is where the 
activating pathways converge and the subsequent steps are similar in all three. The eventual 
result is the formation of a membrane attack complex C5b-9 which kills the pathogen by 
bursting its membrane or wall (Biesecker et al. 1979, Podack et al. 1979). 
Each MBL polypeptide is made up of 4 regions, C-terminal domain, collagen-like region,    
α-helical coiled-coil neck and the carbohydrate-recognition domain (CRD). Figure 1.6 shows 
the structure of the MBL protein and the encoding MBL2 gene. The CRD part of the MBL as 
its name suggests is involved in the selective binding to specific carbohydrates on the 
pathogen surface (Weis et al. 1992, Håkansson et al. 1999). The α-helical neck region 
bridges the CRD and the collagen-like domain. The neck region is involved in the 
trimerisation of the polypeptide units of the MBL and the subsequent oligomerisation of the 
trimers into multimers (Kishore et al. 1997). The collagen-like domain is mainly responsible 
for interaction with MASPs in the cascade that leads to complement activation               














Figure 1.5: Complement system activation pathways. There are three main activation pathways 
that converge at the C3 convertase stage. The final product of all pathways is the formation of the 
membrane attack complex (MAC) which kills the invading pathogen whilst other by-products 
facilitate microbial opsonisation and other anaphylactic processes. 
 
Stabilisation of multimers is a function of the cysteine rich N-terminal domain of the MBL 
which forms strong disulphide bridges between monomers in the folded structure         
(Wallis et al. 2008). Through multimerisation, MBL forms structures with six trimers giving 
an 18 polypeptide complex that resembles a bouquet of flowers (Garred et al. 2006). 
Multimerisation is crucial for the overall affinity of the lectin towards carbohydrates on 
pathogen surfaces and failure to assemble into these structures can result in poor innate 
















Figure 1.6: Schematic representation of MBL2 gene, MBL polypeptide and tetramer 
structures. The gene shows the exons and their corresponding polypeptide regions whilst the bottom 
panel shows polypeptides combine into trimers which in turn combine to form the tetramers    
(adapted from Garred et al. 2006). 
The MBL2 is a 6.32 kb gene located on chromosome 10q11.2-21 (NCBI). Polymorphisms in 
its promoter region and exon1 have been reported to interfere with the overall function of the 
lectin. Three independent missense SNPs in exon 1 (154C>T, 161G>A, 170G>A) result in 
the following amino acid changes; R52C, G54D, G57E alternatively named „D‟, „B‟ and „C‟ 
respectively whilst the wild-type allele is “A”. The B, C and D alleles collectively make up 
the “O” genotype (Sumiya et al. 1991, Lipscombe et al. 1992, Madsen et al. 1998). These 
SNPs alter the amino acid sequence in the first part of the collagenous region of the MBL 
near the cysteine rich domain which interferes with oligomerisation of the MBL trimers 














The distribution of the MBL2 exon 1 alleles differs in different populations with African 
populations predominantly carrying the C allele whilst Caucasians have the B allele mostly 
(Lipscombe et al. 1992, Madsen et al. 1998). In the MBL2 promoter region SNPs, -550G>C 
(-550H/L), -221C>G (-221X/Y) and +4C>T (+4P/Q) in 5` UTR have been reported to affect 
MBL2 expression (Madsen et al. 1995). Due to these polymorphisms, MBL levels in healthy 
individuals may vary up to 1000 fold (Crosdale et al. 2000). The -550G, -221C and +4T 
variants have been reported to result in low and poorly oligomerised MBL which is 
associated with poor prognosis in meningococcal disease and viral hepatitis (Koutsounaki et 
al. 2008, Brouwer et al. 2009).  
Antiviral mechanisms of MBL against HIV involve the lectin binding to high mannose 
oligosaccharides on HIV gp120 making the gp120 unavailable for HIV attachment to host 
cell, thus, blocking the virus from entering the host cell (Saifuddin et al. 2000). MBL also 
neutralises HIV by blocking the virus‟ interaction with dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN) (Spear et al. 2003). DC-SIGN is a C-
type lectin receptor expressed on macrophages and dendritic cells that binds to mannose 
chains on HIV in a process that aids the virus in infecting host cells (Geijtenbeck et al. 2000). 
DC-SIGN is expressed on macrophage subsets that infest the placenta and therefore has been 
implicated in HIV MTCT (Soilleux et al. 2001). Studies among Zimbabweans have reported 
increased risk of MTCT in pregnant women carrying certain genetic variants in the 
promoters and exons of DC-SIGN and DC-SIGNR genes (Boily-Larouche et al. 2009, 2012). 
The current study focuses on the possible role of MBL2 polymorphism on HIV transmission 













A study among Argentinians demonstrated that MBL2 haplotype XA/XA associated with risk 
of acquiring HIV and accelerated progression to AIDS in children (Mangano et al. 2008). 
Another study among children born to HIV-infected mothers, reported that possession of an 
MBL2 O allele was associated with accelerated HIV disease and a tendency to develop 
neurocognitive impairment in children younger than 2 years of age (Singh et al. 2008). MBL2 
genetic variations have also been linked with opportunistic organisms that tend to cause 
neurological complications such as cytomegalovirus (Hu et al. 2010), pneumococcal 
meningitis (Ou et al. 2011) and tuberculosis (TB) (Thye et al. 2011). This suggests that MBL 























1.10 Aims and Objectives 
1.10.1 Aims 
Given the qualitative and quantitative differences in the distribution of HIV/AIDS restriction 
gene variants among populations and the lack of concordance on their effects on HIV 
infection, disease progression and neurocognitive function, the overall aims of the study were 
to describe variation in HIV/AIDS restriction genes in children born to HIV-infected mothers 
and to determine the possible role of the genetic variants in HIV infection and neurocognitive 
function. 
1.10.2 Objectives 
In order to realise our aims, the following objectives were set; 
• To genotype for genetic variants in CCR2, CX3CR1, RANTES, SDF1, APOBEC3G and 
MBL2 genes among HIV-exposed infected (EI), HIV-exposed uninfected (EU) and 
healthy unexposed (UEUI) children 
• To determine association between genetic variants and HIV infection by comparing 
genotype and allele frequencies between HIV EI and EU children  
• To investigate association between genetic variation and neurocognitive function  
• To correlate genotypes with phenotypes such as CD4+ T-cell count, haemoglobin and 
















There is a large body of information linking genetic polymorphism to HIV outcomes but 
most studies have been done on Caucasian populations with limited information available on 
Africans. The distribution of antiviral gene variants significantly differs between populations 
and conclusions cannot be made based on Western studies alone. In addition, the distribution 
of HIV subtypes differs among populations with Europe and America having subtype B 
predominantly whilst subtype C is predominant in Africa (Buonaguro et al. 2007). The 
virulence of HIV subtypes is not the same as evidenced by the difference in HIV prevalence 
across the world.   Given this it is important to investigate the distribution and effects of 
HIV/AIDS restriction genes in the African populations.  
HIV is transmitted through sexual contact mainly, thus, research has been prioritised in 
adults compared to children.  However genetic variation seems to play a significant role in 
paediatric HIV infection. Up to 60% of children perinatally exposed to HIV are born 
uninfected without any intervention suggesting that inter-individual differences play a part in 
evading infection (De Cock et al. 2000). We therefore hypothesise that if certain allelic 
variants are protective aga nst HIV infection then their frequencies would be higher among 
the HIV exposed but uninfected children compared to the exposed and infected.  
Identifying genetic variants that influence HIV transmission and disease progression can help 
predict disease course and guide therapy. The information will also provide new therapeutic 
targets for vaccine and drug development. With current ARVs threatened by drug resistance 
and adverse side effects, new antiviral therapeutics are a priority and some promising targets 
include the use of co-receptor gene mutations such as evidenced by the CCR5 antagonist 













 In this ART era, children born infected with HIV have a better chance of surviving into 
adolescence and adulthood where they enrol into different academic and intellectual 
curricula. Knowledge of the relationship between genetic factors and neurocognitive 
development means a forecast of who is vulnerable can help policy makers and health 
providers to provide appropriate care and guide the children into possible careers. A lot of 
work has been done on the effect of genetic variants on HIV disease progression but little is 
known about how the genes affect neurocognitive development yet cognitive deficits are the 























2 CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Study participants and sample collection 
2.1.1 Historical perspective of cohort 
Participants were recruited from the Better Health for The African Mother and Child 
(BHAMC) cohort (Kurewa et al. 2011). This is a longitudinal study of mother-baby pairs 
who have been followed up since 2002 at three Harare peri-urban clinics in Epworth, St 
Mary′s Chitungwiza and Seke North. The history of the cohort and recruitment of participants 
for the current study is shown in Figure 2.1. The cohort started with 1050 pregnant women 
presenting for antenatal care who were recruited into a Prevention of Mother-to-Child 
Transmission (PMTCT) program at 36 weeks of gestation. 479 (46%) tested positive for HIV 
whilst 571 (54%) were HIV seronegative on enrolment into study. The HIV-infected mothers 
and their infants were given 200mg and 2mg/kg single dose nevirapine (sdNVP) respectively 
within 72 hours of delivery as prophylaxis to prevent infection of the child.  
Of the 571 HIV-negative mothers, 441 (77%) gave birth to live babies, 126 (22%) were lost 
to follow up and four (1%) had still births. On the other hand, the 479 HIV seropositive 
mothers gave birth to 401(84%) live infants, 73 (15%) were lost to follow up and five had 
still births (1%). After five years of follow-up, 391(97%) of the HIV-exposed children had 
been screened for HIV at least once with 97 (25%) of them testing positive                 
(Kurewa et al. 2011). A total of 23 (23%) of the HIV-infected children died within the first 














Key: LTF- loss to follow-up, EI-exposed infected, EU- exposed uninfected, UEUI-unexposed uninfected, MSCA-McCarty Scale of Children‟s Abilities 













2.1.2 Current study participants 
A total of 116 children who were 7-9 years of age were recruited for this sub-study. These 
included 34 children perinatally-infected with HIV (EI) who were on ART for at least six 
months prior to sample collection and officially enrolled at a primary school and 82 healthy 
HIV-uninfected children (EU+UEUI) of the same age who were recruited as controls.  The 
HIV-uninfected children fell into two groups, one comprising of 39 born to HIV-infected 
mothers (exposed uninfected, EU) and the other of 43 born to uninfected mothers (UEUI). 
All participants were of indigenous black African origin. The study received ethics clearance 
from the Medical Research Council of Zimbabwe and the Ethics Research Committee of 
Faculty of Health Sciences, UCT. Written consent was obtained from the parents/guardian of 
each child before a sample could be collected. A 2-5ml EDTA blood sample was collected 
from each child and transported to the laboratory for CD4+ T-cell count within six hours of 
collection. The remaining sample was stored at -80˚C for genotyping purposes.  
A questionnaire was administered to the parent/guardian to determine each child‟s 
demographic information and medical history for the three months prior to the data 
collection. Occurrence of any of the common morbidities such as fever, diarrhoea, cough, ear 
discharge and vomiting at least once in the three months preceding sample collection was 
recorded. Neurocognitive function was tested using the McCarthy Scale of Children‟s 
Abilities (MSCA) as part of a bigger study titled; Neurodevelopment and Growth among 
Peri-urban Zimbabwean School Age Children from a High Prevalence HIV Community. The 
MSCA tool was translated into Shona language with help of a linguist and then administered 













The MSCA tested three attributes of cognitive function (verbal, perceptive-performance and 
quantitative) and a general cognitive ability which reflected the overall cognitive function of 
the child. The tool assesses performance of each child on assigned tasks and gives a score 
from which a cognitive index scores can be calculated. The verbal aspect assesses cognitive 
tasks related to verbal information processing whilst perceptive-performance assesses 
information processing during manual tasks. The general cognitive index score takes into 
account all aspects of cognitive function including memory, gross and fine motor skills 
(Guxens et al. 2009). For analysis, cut-off points were set at 30 for verbal, perceptive-
performance and quantitative cognitive index scores. The cut-off for the general cognitive 
index score was 68. The children were categorised into cognitively unimpaired and impaired 
if they fell above and below cut-off, respectively for each attribute. Genotype frequencies 
were compared between the groups of neuro-cognitively impaired and the normal to 
determine association between genetic variation and neurocognitive function in HIV infected 
or uninfected children.   
2.2 Preparation of biological samples for genotyping 
2.2.1 Extraction of genomic DNA from whole blood 
Genomic DNA was extracted from blood using the Nucleospin® Blood L kit (Macherey-
Nagel, Germany) according to the manufacturer‟s instructions. In summary, 2ml of blood 
was mixed 150μl of enzyme proteinase K in a Tris-hydrochloride buffered reaction 
containing chaotropic ions.  The mixture was vigorously vortexed to lyse blood cells before 
incubation at 56˚C for 15 minutes (min) to allow proteinase K to digest the proteins in the 
lysate. 2ml of absolute ethanol was then added to the lysate to facilitate binding of DNA 













The chaotropic ions together with ethanol destabilise the remaining protein contaminants 
making them water insoluble. This allows the DNA to bind to the membrane whilst ethanol 
washes away all the destabilised macromolecules. The binding stage was followed by two 
ethanol washes to remove any extra contaminants. The silica membrane was transferred to a 
clean tube into which the silica membrane bound DNA was eluted using a 200μl of 5mM 
alkaline Tris-Ethyleneiaminetetraacetic acid (Tris-EDTA) buffer. The EDTA chelates 
calcium ions to prevent any residual DNase enzyme from degrading the purified DNA. 
Before the DNA was stored or used for genotyping, it was checked for quality and quantified 
as described in the next section. 
2.2.2 Determination of DNA integrity 
To check integrity of the extracted genomic DNA, 5μl of the eluted DNA solution was 
electrophoresed on 1% agarose gel stained with ethidium bromide (EtBr) for 1 hour at 100V 
in Tris-Borate EDTA (TBE) buffer. Agarose gel electrophoresis is a method of separating 
DNA fragments according to their size using direct electric current. Agarose is a 
polysaccharide whose chains bind non-covalently creating a gel with sieving pores of 
different sizes depending on the concentration of the agarose. Since DNA has a negative 
phosphate backbone and uniform mass/charge ratio it migrates towards the positive charge at 
rates governed by the size of fragments (Helling et al. 1974). For visualisation of the DNA 
fragments, the gel is stained with a nucleic dye that intercalates between the bases of the 
DNA such as ethidium bromide (EtBr) or SYBR Green. These dyes emit fluorescent light 
which is visible under ultra-violet (UV) light. To approximate the sizes of the DNA 
fragments, a molecular weight marker which is a mixture of DNA fragments of known sizes 













Good quality DNA shows clear and clean band with no smearing after electrophoresis. After 
confirming the quality of DNA, it is important to measure the amount of DNA in each sample 
so that a known amount can used for subsequent experiments.  
2.2.3 Quantification of isolated genomic DNA 
Genomic DNA was quantified using spectrophotometry (NanoDrop® ND-500) by measuring 
absorbance of the DNA at 230nm, 260nm and 280nm wavelengths. All nucleic acids, RNA, 
DNA, single stranded or double stranded absorb light at 260nm but at different rates. 
Calculation of DNA concentration is based on the equation that one optical density at 260nm 
(OD260) equals 50ng/µl of double stranded DNA (Gallagher et al. 1989).  The 260/280 and 
260/230 ratios are used to check for presence of contaminants in the DNA solution. Values of 
1.8 and 2.0-2.22 for OD260/OD280 and OD260/OD230 ratios respectively indicate high DNA 
purity. Protein and phenol absorb light at 280nm wavelength whilst carbohydrates, phenol 
and residual guanidine from DNA extraction absorb at 230nm (Gallagher et al. 1989). 
Presence of contaminants lowers the expected ratios. The concentration of each DNA sample 
was adjusted to a working concentration of 50ng/μl using sterile DNA free water.              
The working solutions were then used in PCR based genotyping methods.   
2.3 Genotyping for single nucleotide polymorphisms  
2.3.1 Primer designing 
The success of PCR based genotyping is dependent on use of primers that achieve high 
specificity and yield during amplification. To achieve this careful designing of primers is a 
pre-requisite and several bioinformatics tools have been designed for this purpose. PCR 













Primer 3 allows one to input DNA sequence spanning a region of interest, input the desired 
specifications for the primer and the program selects pairs of potentially useful primers.  
Preferred primers were of length 18 to 21 bases, with guanine-cytidine (GC) content between 
40 to 60% and melting temperatures (Tm) ranging from 57˚C to 63˚C. Primer pairs obtained 
from Primer 3 were analysed using additional online bioinformatics softwares, Primer Blast 
(NCBI) and OligoAnalyzer SciTool (Integrated DNA Technologies®; 
http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/). The Primer Blast package was 
used to confirm if the gene region amplified by a selected pair of primers actually flanked the 
region intended.  
Furthermore, Primer Blast shows the length of the fragment to be amplified, melting 
temperatures of the primers and if the primer pair will also amplify any undesired non-
specific genomic regions. OligoAnalyzer was primarily used to determine possible formation 
of secondary structures such as hairpins, self-dimers and hetero-dimers within and between 
the primer pairs. If secondary structures detected formed bonds requiring total enthalpy 
change (∆G) of more than 5kcal/mole to be broken then the primers were excluded. Hairpin 
structures containing three or more C-G bonds or requiring temperatures above 40 ˚C to melt 
them were also excluded. PCR primer designing however differed slightly from that of 
SNaPshot primers.  
SNaPshot primers have to anneal immediately adjacent to the polymorphic position to be 
genotyped, therefore, only the sense or antisense sequences immediate of that nucleotide 
position can be used. If the adjacent DNA sequences made primers with undesirable 
secondary structures then bases involved in the secondary structure formation were 













Sense primers were preferred but where they remained unfavourable after base adjustment, 
the antisense sequences were opted for. The primers designed were used in PCR to amplify 
DNA fragments for downstream genotyping techniques such as restriction fragment length 
polymorphism and DNA sequencing. 
2.3.2 Polymerase Chain Reaction  
PCR was used to amplify target DNA regions on the genomic DNA template. PCRs were 
optimised to achieve high specificity and yield by adjusting annealing temperatures and 
magnesium ions (Mg
2+
) concentration. A range of annealing temperatures between 50-65˚C 
depending on melting temperature of primers, were tested in a temperature gradient to 
determine the most optimal for each reaction. The annealing temperature achieving clean and 
sharp DNA bands on agarose gel was used in the PCR. If the most optimal annealing 
temperature showed non-specificity or poor yield, the concentration of Mg
2+
 was titrated to 
further optimise the reaction. The primer extension time and number of thermal cycles were 
also considered as part of optimisation. Dimethyl sulfoxide (DMSO) was used to enhance 
PCR where reaction products remained non-specific and/or with low yield after thermal 
cycling conditions adjustment. Once optimal PCR conditions were achieved, DNA fragments 
were amplified in preparation for PCR based genotyping methods such as restriction 
fragment polymorphism and DNA sequencing. The optimal cycling conditions for all PCRs 
done in this study are listed in Table 2.2 and all PCR reactions were confirmed by 
electrophoresing 5µl of the product on 2% agarose gel stained with ethidium bromide at 














2.3.3 Restriction Fragment Length Polymorphism (RFLP) 
Restriction fragment polymorphism is a genotyping method that involves cleavage of DNA 
fragments at target sites using restriction enzymes that recognise specific sequences called 
restriction sites. Fragments generated by the enzyme after incubation with the DNA are 
separated according to size using gel electrophoresis. DNA has a net negative charge due to 
phosphate groups. DNA therefore migrates towards the positive charge under electrical 
current in electrophoresis. The digested DNA forms banding patterns that are consistent with 
the positions that are targeted for restriction or digestion by the restriction enzyme. 
Polymorphisms either create or abolish restriction enzyme sites and this is observed from the 
pattern on the gel. A molecular weight maker is included during the electrophoresis so that 
the DNA fragment sizes may be approximated. Restriction sites on DNA fragments analysed 
in this study were confirmed using an online package called Nebcutter V2.0 (New England 
Bio systems®). In this study, the following SNPs were genotyped using PCR-RFLP; CCR2 
190G>A, CX3CR1 745G>A, CX3CR1 839C>T, SDF1 801G>A, RANTES In1.1T>C, 
APOBEC3G 557>G, APOBEC3G -90C<G and MBL2 170G>A. In addition to RFLP, 
genotyping was also done using DNA sequencing (Sanger) and primer extension mini-
sequencing (SNaPshot®). 
2.3.4 Genotyping by Sanger chain termination sequencing 
DNA sequencing is a genotyping method that involves determination of linear arrangement 
of nucleotides on a DNA fragment. In the Sanger chain termination sequencing, template 
DNA to be sequenced is mixed in a reaction with deoxy-nucleotide triphosphates (dNTPs), 
labelled dideoxy-nucleotide triphosphates (ddNTPs), DNA polymerase enzyme and a primer 













The primer anneals to the template and polymerase enzyme adds dNTPs to the primer‟s 3′ 
end in a process that extends the primer. The ddNTPs in the reaction are also randomly added 
to extending strands but ddNTPs have a hydrogen (–H) instead of a hydroxyl group (–OH) on 
their 3′ end and therefore cannot form phosphodiester bonds with an incoming dNTP. The 
addition of a ddNTP to the strand therefore terminates the extension. Because dNTPs and 
ddNTP are added randomly to extending DNA strands, the process generates a pool of 
terminated fragments of varying lengths (Sanger 1977, Sanger 1980). Each of the four bases 
(G, C, T and A) on the ddNTPs is labelled with a different colour dye. The terminated DNA 
strands are then separated according to size using capillary electrophoresis for analysis giving 
a chain of coloured peaks representative of nucleotide bases at each position. Sanger‟s chain 
termination DNA sequencing technique was used to genotype variants in the promoter and 
exon 1 regions of the MBL2 gene. The principle of Sanger chain termination sequencing has 
been adapted in another genotyping method called minisequencing. 
2.3.5 Genotyping by primer extension minisequencing (SNaPshot®) 
Primer extension mini-sequencing is a SNP detection method based on the annealing of a 
primer adjacent of the 5′ of the nucleotide to be identified on a DNA template. A single 
labelled dideoxy nucleoside triphosphate (ddNTP) is then added to the primer in a process 
catalysed by DNA polymerase enzyme (Syvänen et al. 1990). The ddNTP lacks the hydroxyl 
group needed for formation of the phosphodiester linkage, thus, its incorporation terminates 
the extension hence the term “minisequencing”. SNaPshot® primer extension 
minisequencing is patented by Applied Biosystems. In SNaPshot®, several SNPs can be 
genotyped simultaneously using different primer sizes and ddNTPs labelled with different 













The extended primers are separated according to size using automated capillary 
electrophoresis (ABI PRISM® 3130 Genetic Analysers) and the SNPs can be identified by 
size on the electrophoregram whilst the fluorescent dye on the incorporated ddNTP identifies 
the nucleotide base. To determine the genotypes for all SNaPshot reactions in this study, 5μl 
of SNaPshot products were mixed with 0.3μl GeneScan™-120 LIZ™ size standards and 
4.7μl Hi-Di™ formamide and analysed using capillary electrophoresis on the ABI PRISM® 
3130 Genetic Analyser. The output of the electrophoresis was analysed using the 
GeneMapper® v4 software. The program generates an electrophoregram where alleles appear 
as peaks of different colours and size depending on the base of the nucleotide added and 
length of primer used in the SNaPshot. SNPs, RANTES -403G>A, APOBEC3G (-571G>C, 
197T>C and 199C>G) and MBL2 (-595G>A, -550C>G, -221C>G and +4C>T) were 
investigated using the SNaPshot genotyping technique in the current study. 
Table 2.1: List of fluorescent dyes used in SNaPshot and their corresponding colours 
ddNTP Dye label Colour of analysed data 
A dR6G Green 
C dTAMRA™ Black 
G dR110 Blue 


















2.4 Genotyping of chemokine receptor genes CCR2 and CX3CR1 
Genotyping of CCR2 variants was done using PCR based RFLP. Table 2.2 is a summary of 
the primers, cyclic conditions and enzyme restriction methods used in all RFLP assays in this 
study. The CCR2 190G>A (rs1799864) SNP was genotyped according to a method described 
elsewhere (Martinson et al., 2000) but with minor modifications. To determine CCR2 
190G>A alleles, a 337 base pair (bp) fragment flanking the SNP was amplified in a 25μL 
volume containing 10 picomoles of each of the primers (Table2.2), 200μM dNTP mix, 1X 
buffer (pH 8.3), 1.5mM Mg
2+
, 1U Taq polymerase and 50ng genomic DNA. The cycling 
conditions were as shown in Table 2.2. A 10μl volume of the PCR product was digested 16 
hoursusing 2U of BseGI (FokI) restriction enzyme and electrophosed on 2% agarose gel 
stained with EtBr at 120V for 1h. The CCR2 190A allele is susceptible to BseGI restriction 
activity, thus the PCR product is cleaved to give two fragments of 228bp and 109bp whilst 
CCR2 190G allele is resistant to BseGI activity leaving the 337bp PCR product undigested. 
The structure of the CCR2 gene and position of the 190G>A SNP are shown in Figure 2.2.  
 













In addition to CCR2, another chemokine receptor gene CX3CR1 also formed part of this 
study. Two SNPs in CX3CR1 745G>A (rs3732379) and CX3CR1 839C>T (rs3732378) were 
genotyped using PCR-RFLP (Table 2.2). The positions of the two SNPs on the gene are 
shown on the schematic diagram of CX3CR1 shown in Figure 2.3. The 745G>A genotyping 
was carried out according to the method of Nasar et al. (2008) with minor modifications 
(Nassar et al. 2008). A 311bp gene region flanking the 745G>A position was amplified in a 
reaction mixture consisting of 10 picomoles of forward and reverse primers (Table 2.2), 
200μM dNTP mixture, 1X buffer (pH 8.3), 1.5mM Mg
2+
, 1U of Taq polymerase enzyme and 
50ng genomic DNA in a 25μl volume. The thermal-cycling conditions are shown in Table 
2.2. To determine the genotypes, 10μl PCR fragment were digested using 5U of Psp1406I 
(AclI) restriction enzyme. For successful digestion, 3U of enzyme were added at beginning of 
reaction and 2U more supplemented three hours into the 16h digestion to ensure complete 
digestion. In the presence of the 745G allele, the enzyme cleaves the PCR product into two 
bands of 204bp and 107bp. Presence of the A allele disrupts the cleavage site leaving the 
311bp PCR fragment undigested.  
 














Table 2.2: PCR-RFLP conditions for all SNPs investigated using the genotyping method 








 94˚C-30s, 60˚C-30s, 
72˚C-30s, 72˚C-5min 
BseGI                   
 
5′...GGATGNN↓N...3′ 
3′...CCTAC↑NNN...5′               
337bp G-337 




























HpaII    5′...C↓CGG...3′ 
3′...GGC↑C...5′                                  













































Key: RE- Restriction enzyme, A3G- APOBEC3G 
*Cycling conditions in order, denaturation, primer annealing, primer extension, final extension. 
*All cycling conditions started with an initial denaturation step at 94˚C for 5min which is not shown. 













To genotype CX3CR1 839C>T variants, 10 picomoles of each of the primers sense and 
antisense (Table 2.2) were mixed with 200μM dNTP mixture, 1X PCR buffer (pH 8.3),  
1.5mM MgCl
2+
, 1U of Taq polymerase enzyme and 50ng genomic DNA in a 25μl volume 
PCR mix to amplify a 377bp fragment. A 10μl volume of the PCR product was digested 
using 6U of BsmBI restriction enzyme for 16 hours at 37˚C. The digestion products were 
electrophoresed on 2% agarose gel for 1 hour at 100V in the presence of EtBr as the DNA 
staining chemical. In the presence of the 839C allele, the enzyme has two restriction sites 
resulting in three fragments of 189bp, 113bp and 75bp whilst the 839T allele disrupts one of 
the restriction sites giving two fragments 113 and 264bp long.  
2.5 Genotyping of chemokine genes SDF1 and RANTES 
The genotyping of SDF1 801G>A (rs1801157) was done as described elsewhere (Balotta et 
al. 1999) but with minor modifications. 10 picomoles of each of forward and reverse primers 
(Table 2.2) were added to a PCR reaction mixture consisting of, 200μM dNTP mixture, 1 X 
PCR buffer, 1.0mM MgCl2, 5% DMSO, 1U of Taq polymerase enzyme and 50ng genomic 
DNA in a 25μl reaction volume. The cycling conditions were as shown in Table 2.2. A 302bp 
fragment was the PCR product of interest confirmed by electrophoresis of 5μl of the PCR 
product on 2% agarose gel with EtBr as DNA staining chemical for an hour at 100V. 10μl of 
PCR product were then digested 16 hours using 2U MspI (HpaII) restriction enzyme to 
determine the genotypes. The products of the digestion were run on 2% agarose gel 
containing EtBr stain for 1h at 100V to separate them according to size. The 801G allele is 
digested into two fragments of 202 and 100bp sizes. The A variant disrupts the MspI 
restriction site leaving the 302bp fragment undigested. Figure 2.4 shows a schematic of the 















Two SNPs, RANTES In1.1T>C and RANTES -403G>A (Figure 2.5) were studied using PCR-
RFLP and SNaPshot® respectively.  In1.1T>C genotyping was done according to a method 
described by elsewhere but with a few modifications (Qian et al. 2008). A 343bp DNA region 
incorporating the In1.1T>C polymorphism was amplified using a PCR reaction mixture 
comprising of 10 picomoles of the each primer, 200μl of dNTP mixture,  1X PCR buffer, 1.0 
mM Mg2+, 1U of Taq polymerase enzyme and 50ng genomic DNA in a 25μl volume. A 10μl 
volume of the PCR products was then digested using 3U of MboII restriction enzyme by 
incubating at 37˚C overnight. The digestion products were electrophoresed on 2% agarose gel 
stained with EtBr for 1 hour at 120V in TBE buffer. The 343bp PCR product remains 
undigested in the presence of In1.1T allele but the In1.1C allele introduces an MboII 
restriction site yielding two fragments, 225bp and 118bp.  
Figure 2.4: Schematic representation of the SDF1 gene structure showing the position of 














Figure 2.5: Schematic representation of the RANTES gene structure showing the position of 
the two SNPs investigated 
 
PCR based SNaPshot was the method of choice for RANTES -403G>A genotyping. The 
primers, PCR and SNaPshot cycling conditions for all SNaPshot reactions done in this study 
are shown in Table 2.3. The PCR reaction used to amplify a 527bp fragment flanking the 
RANTES -403G>A SNP consisted of 10 picomoles of each of the forward and reverse 
primers, 200μM dNTP mixture, 1X PCR buffer, 1.5mM MgCl
2+
, 1U of Taq polymerase 
enzyme and 50ng genomic DNA in a 25μl volume. In preparation for SNaPshot, the PCR 
products were purified using exonuclease (Fermentas®) and Thermo sensitive Alkaline 
Phosphatase enzymes (FastAP™). The exonuclease (exo) digests excess primer whilst the 
FastAP™ neutralises extra dNTPs by removing the phosphate group. For each purification 
reaction, 5μl purified PCR product were mixed with 1U FastAP™ and 2U exo enzymes in a 
10μl volume and incubated for 1 hour at 37˚C before deactivating the enzyme by heating at 














The SNaPshot reaction mixture was made up of 20 picomoles of primer (Table 2.3), 1μl 
purified PCR product, 1μl of the SNaPshot multiplex ready reaction mix and made up to 10μl 
volume with DNA-free water. The reaction mixture was incubated for 25 cycles of; 
denaturation at 96˚C for 10s, primer annealing at 50˚C for 5s and primer extension at 60˚C 
for 30s. Excess fluorescently labelled ddNTPs were neutralised by digesting the reaction 
products with 1U FastAP™ at 37˚C for 1 hour before heat-inactivating the enzyme at 75˚C 
for 15 min. The SNaPshot products were then analysed on the ABI PRISM® 3130 Genetic 
Analyser as described in section 2.3.5 Blue peak of size 34.2 on the electrophoregram was 
interpreted as -403G allele while a green peak at the same position represented the -403A 
allele. In addition to chemokine receptors and chemokines, this study also investigated 
polymorphism in two genes involved in the innate immune system through pathogen pattern 














Table 2.3: Primers and cycling conditions for PCR based SNaPshot genotyping 











94˚C-5m, 94 ˚C-30s, 60 ˚C-
30s, 72 ˚C-30s, 72 ˚C-30s 








94˚C-5m, 94 ˚C-30s, 55 ˚C-
30s, 72 ˚C-30s, 72 ˚C-30s 







94˚C-5m, 94 ˚C-30s, 60 ˚C-
30s, 72 ˚C-30s, 72 ˚C-30s 








94˚C-5m, 94 ˚C-30s, 60 ˚C-
30s, 72 ˚C-30s, 72 ˚C-30s 




94˚C-5m, 94 ˚C-30s, 64 ˚C-
















N/A  96˚C-10s, 50˚C-5s, 
60˚C- 30s. 
Key: A3G-APOBEC3G, SS- SNaPshot primer, N/A-not applicable 













2.6 Genotyping of innate immune factor genes 
2.6.1 Genotyping of APOBEC3G gene variants 
Five SNPs were investigated in the APOBEC3G gene; two in the promoter region (-571G>C; 
rs5757463 and -90C>G; rs5750743), one in exon 4 (557A>G; rs8177832) and two in introns 
(197T>C/ rs3736685 and 199C>G/ rs2294367). The five SNPs are shown in the schematic 
diagram of the gene in Figure 2.6. Variation at 557A>G and -90C>G were genotyped using 
PCR-RFLP whilst SNaPshot was used to genotype the remaining three. 
 
 
Figure 2.6: Schematic representation of the APOBEC3G gene showing all the SNPs studied 
 
The APOBEC3G 557A>G polymorphism in exon 4 of APOBEC3G gene was determined 
using a method previously described elsewhere but with minor modifications (An et al. 2004). 
A 409bp DNA fragment flanking the 557A>G site was generated in a  25μl PCR reaction 
mixture containing 10 picomoles of each primer, 200μM of dNTP mixture, 1X PCR buffer, 
0.5mM Mg
2+













The PCR cycling conditions are shown in Table 2.2. In the final step of the genotyping 
procedure, a 10μl volume of the PCR product was subsequently digested using 2U of HhaI 
restriction enzyme by incubating 16 hoursat 37˚C. The G allele has two restriction sites 
resulting in the generation of three fragments; 194bp, 145bp and 70bp. The A allele results in 
the loss of one restriction site, thus, after digestion with HhaI only two bands, 339bp and 70bp 
are observed.  
Genotyping for APOBEC3G-90C>G variants involved the amplification of a 355bp fragment 
flanking the SNP in a PCR reaction mixture consisting of 10 picomoles of each of the primers 
(Table 2.2), 200μM dNTPs, 1X buffer (pH 8.3),  1.5mM Mg
2+
, 1U Taq polymerase and 50ng 
genomic DNA in a total volume of 25μl. Cycling conditions were as shown in Table 2.2. PCR 
specificity and quantity was checked by electrophoresing 5μl of the PCR product on 2% 
agarose gel with EtBr stain at 100V for 1 hour before visualisation under UV light. For allele 
determination, 10μl of PCR products were incubated with 5U of AvaI restriction enzyme at 
37˚C 16 hoursin a 20μl volume. The digested DNA was then analysed after electrophoresis on 
2% agarose gel stained with EtBr. The enzyme cleaved the C variant into two fragments, 
259bp and 96bp whilst the G variant led to the loss of the restriction site, thus, resulting in an 
undigested PCR product of 355bp fragment. In addition to the two APOBEC3G SNPs 
genotyped by PCR-RFLP, three more were genotyped using SNaPshot.  
The PCR based primer extension method was used to genotype three SNPs in the APOBEC3G 
gene; -571G>C, 197T>C and 199C>G. Three sets of sense and antisense primer pairs were 
designed to amplify three DNA fragments in APOBEC3G promoter, intron 3 and intron 4 
flanking SNPs, rs5757463G>C, rs3736685T>C and rs2294367C>G respectively  (Table 2.3). 













Each PCR consisted of 10 picomoles of each of the respective forward and reverse primers, 
50ng of genomic DNA, 1X PCR buffer (pH 8.3), 1.5mM Mg
2+
, 200μM dNTPs mixture, 1U 
Taq polymerase enzyme and 50ng genomic DNA in a 25μL volume. The thermal cycling 
conditions are shown in Table 2.3. The PCR products were confirmed by electrophoresing 5µl 
on 2% agarose gel stained with EtBr at 100V for 1hour before they could be used in SNaPshot 
reaction. To prepare the PCR products for SNaPshot reaction, excess primers and dNTPs from 
the PCR were digested by incubating 5μl of each PCR product with 1U FastAP™ and 2U 
exonuclease enzymes in a 10μl volume at 37˚C for 1 hour.  
Genotyping of APOBEC3G -571G>C and 199C>G variants was done simultaneously in a 
multiplex SNaPshot reaction. The reaction comprised of 13.3 picomoles of the -571G>C 
primer , 6.7 picomoles of 199C>G primer (Table 2.3), 5μl of APOBEC3G promoter and exon 
4  purified PCR products mixed in a 1:1 ratio and 2µl of SNaPshot® Multiplex Ready 
Reaction Mixture in a 10μl reaction. Thermal cycling conditions consisted of 25 cycles of; 
denaturation at 96˚C for 10s, primer annealing at 50˚C for 5s and primer extension at 60˚C for 
30s. Unattached ddNTPs from the SNaPshot reaction were inactivated by digesting the 
products with 1U FastAP™ for 1h before heat inactivating the enzyme at 75 ˚C for 15 min. To 
determine the -571G>C and 199 alleles, the SNaPshot products were analysed through 
capillary electrophoresis as described in section 2.3.5. Blue and black peaks at position 40.5 
on the electrophoregram represented -571G and -571C alleles respectively. Because an 
antisense primer was used to genotype 199C>G variants, the blue and black peaks at position 
49 represented the 199C and G alleles respectively. Unlike -571G>C and 199C>G SNPs that 














The APOBEC3G 197T>C SNaPshot reaction mixture was made up of 20 picomoles of the 
primer (Table 2.3), 1μl purified PCR product, 1μl of the SNaPshot® Multiplex Ready 
Reaction Mixture made up to 10μl volume with DNA-free water. The cycling conditions 
consisted of 25 cycles of denaturation at 96˚C for 10s, annealing at 50˚C for 5s and primer 
extension at 60˚C for 30s. Excess ddNTPs from the SNaPshot were digested using 1U of fast 
AP incubated at 37˚C for 60 and 75˚C for 15min to heat-inactivate the enzyme. To determine 
the 197T>C alleles, 5μl of the SNaPshot products were mixed with 0.3μl GeneScan™-120 
LIZ™ size standard and 4.7μl Hi-Di™ formamide and separated according to size using 
capillary electrophoresis on the ABI PRISM® 3130 Genetic Analyser 3130. Presence of a red 
peak on position 35.5 on the electrophoregram represented a 197T allele while a black peak 
was interpreted as 197C allele.  
2.6.2 Genotyping of MBL2 gene 
The expression of the mannose binding lectin (MBL) protein and assembly of its polypeptides 
into functional units seems to be affected by polymorphism in the promoter and exon 1 
regions of the gene encoding the protein (MBL2).To investigate variation of previously 
reported and possible novel SNPs, a 1187bp region of the MBL2 stretching from promoter to 
intron 1 was amplified and subsequently sequenced using PCR based Sanger chain 
termination sequencing. Figure 2.7 is a schematic depiction of MBL2 showing the region 






























-550C>G  (rs11003124) 
SNaPshot®
 
Figure 2.7: Schematic representation of the MBL2 gene. The top panel shows the full gene 
structure whilst the bottom one zooms in on the region that was investigated in this study. The arrows 
indicate the positions of the SNPs that were genotyped and the genotyping methods employed. 
Ten picomoles of each of the sense and antisense primers were mixed with; 200μM dNTPs, 
1X TE buffer , 1.5mM Mg2+, 1U Taq polymerase and 50ng genomic DNA in a 25μl PCR 
reaction mixture. The cycling conditions were as follows; initial denaturation at 94˚C for 
5min, followed by 35 cycles denaturation , primer annealing and primer extension at  94˚C,  
64˚Cand 72˚C respectively for 30s at each step. The reaction was finalised by an extension 
step of 5 min at 72˚C. The PCR was confirmed by electrophoresis of 5μl of the PCR product 
on 2% agarose gel containing GR green nucleic acid stain at 100V for 1 hour in TBE buffer. 
In preparation for the sequencing, 5μl of the PCR products were incubated with1U FastAP™ 
and 2U exonuclease enzymes in a 20μl volume at 37˚C for 1 hour before heat-inactivating the 
enzyme at 75˚C for 15 min. To allow the appropriate amount of PCR amplified DNA to be 
added to subsequent sequencing reaction, the purified PCR product was quantified by 













The sequencing reaction mixture for the sense strand genotyping consisted of; 10 picomoles of 
the sense primer, 300ng of the purified PCR product,  2μl of BigDye® Terminator Ready 
Reaction Mix (containing fluorescently labelled ddNTPs, dNTPs and Taq polymerase) and 4μl 
BigDye® sequencing buffer (ABI® PRISM) in a 20μl volume.  For antisense strand 
sequencing, a similar reaction mixture was prepared but with the antisense primer in place of 
the sense primer. Thermal cycling was done as follows; initial denaturation at 98˚C for 5 min 
followed by 30 cycles of denaturation at 96˚C, primer annealing at 50˚C and extension at 60 
˚C for 30s, 15s and 4 min respectively. The sequenced DNA was then precipitated out of 
solution using absolute alcohol and 0.3M sodium acetate (pH 5.5) at -20˚C for 2 hours.  
The precipitate was pelleted by spinning down at 5000rpm for 10 min and the supernatant 
decanted.  The ethanol in the precipitation disrupts the balance of charge in water resulting in 
negatively charged DNA binding to positively charged sodium ions provided by the low 
sodium acetate forcing the DNA to precipitate out of solution. The DNA pellet was washed 
using 50μl of 70% alcohol to remove excess salts by spinning down in a centrifuge at 
5000rpm for 10 min before decanting the supernatant.  The DNA pellet was then air dried and 
resuspended in 10μl DNA free water. A volume of 5μl of the resuspended DNA was mixed 
with 8μl of HIDI™ (BigDye® Terminator sequencing standard) for capillary electrophoresis 
of the DNA on the ABI® PRISM 3130 Genetic Analyser.  
The sequences were analysed using the Lasergene® 10 software (DNA star). Lasergene® 
generates an electrophoregram where nucleotide bases are read as C for blue peaks, T for red, 
G for black and A for the green peaks. The sequences were manually inspected and edited in 
cases where the software incorrectly called the bases due to blobs, low signal or other 
artefacts. Alignment with a reference sequence from NCBI databases was used to detect 













Sequencing of MBL2 promoter and exon 1 region served as a screening process for the 
presence of previously reported SNPs whose allelic variants have been linked with HIV 
infection or disease progression. Sequencing was also aimed at detection of possible novel 
variants in the MBL2 promoter. Using the sequencing results as a guideline for further 
investigation, three previously reported SNPs and a novel SNPs were genotyped using other 
methods in samples that had not been sequenced. MBL2 -595G>A (novel), -221C>G 
(rs7096206) and +4C>T (rs7095891), where genotyped using SNaPshot while PCR-RFLP 
was the method of choice for 170G>A (rs1800451) genotyping.  
MBL2 -595G>A, -221C>G and +4C>T are located within 600bp of each other, thus, the same 
1187bp PCR fragment used for sequencing was used for the SNaPshot. In preparation for 
SNaPshot, the PCR products were purified using exonuclease and FastAP™ enzymes. The 
purification reaction mixture contained; 5μl purified PCR product, 1U FastAP™ and 2U exo 
in a 10μl volume. This was incubated for 1 hour at 37˚C before inactivating the enzymes by 
heating at 75˚C for 15 min. Each of the three SNPs (-595G>A, -221C>G and +4C>T) was 
genotyped in a separate single-plex SNaPshot reaction. However, reaction conditions were the 
same for all. Each SNaPshot reaction mix was made up of 20 picomoles of the respective 
primer, 1μl purified PCR product and 1μl of the SNaPshot Multiplex Ready Reaction Mix 
made up to a 10μl volume with DNA-free water. The reaction mixture was incubated for 25 
cycles of; denaturation at 96˚C for 10s, primer annealing at 50˚C for 5s and primer extension 
at 60˚C for 30s. Excess fluorescently labelled ddNTPs from the SNaPshot reaction were 
neutralised by digesting the reaction products with 1U FastAP at 37˚C for 1 hour before heat-














To determine the nucleotide added to each primer, 5μl of the SNaPshot products were mixed 
with 0.3μl GeneScan™-120 LIZ™ size standard and 4.7μl Hi-Di™ formamide and separated 
according to size using capillary electrophoresis on the ABI PRISM® 3130 Genetic Analyser 
3130. Output of the electrophoresis is on an electrophoregram generated using the Gene 
Mapper software. Because all three SNaPshot reactions were carried out using antisense 
primers the colour peaks seen on the electrophoregram were representative of the reverse 
complement of the alleles. The -595G and -595A alleles were therefore seen as black and red 
peaks respectively at position 35.5 on the electrophoregram. Blue and black peaks at 32 
represented -221C and -221G alleles respectively whilst blue and green at 41 were read as 
+4C and +4T alleles.  
The MBL2 170G>A SNP was genotyped using PCR-RFLP. A 213bp DNA region 
incorporating the 170G>A polymorphism was amplified in a PCR reaction mixture composed 
of; 10 picomoles of the each primer, 200μl of dNTP mixture,  1X PCR buffer, 1.0 mM Mg
2+
, 
1U of Taq polymerase enzyme and 50ng genomic DNA in a 25μl volume. The cycling 
program involved a genomic DNA denaturation step at 94˚C for 5min followed by 35 cycles 
of; denaturation at 94˚C for 30s, annealing at 62˚C for 30s, extension at 72˚C for 30s and final 
extension for 5min at 72˚C. A 10μl volume of the PCR products was digested using 3U of 
MboII restriction enzyme 16 hoursat 37˚C. The digestion products were electrophoresed on 
2% agarose gel stained containing EtBr stain for 1 hour at 100V in TBE. The 213bp PCR 
product remains undigested in the presence of 170G allele while the 170A allele introduces a 















2.7 Statistical Analysis 
Genotype and allele frequencies in the HIV exposed infected (EI), exposed uninfected (EU) 
and unexposed children cases and controls were calculated using Stata 11.2 (StataCorp LP, 
Texas USA) and/or SHEsis online version (Shi & He. 2005). Genotype frequency calculation 
involves counting the number of individuals carrying a genotype in a group and dividing by 
the total number of individuals in the group. To determine minor allele frequency the number 
of homozygotes for the allele is multiplied by two, added to the number of heterozygotes and 
divided by twice the number of individuals in the group. Fit to Hardy Weinberg Equilibrium 
(HWE) was tested using chi-squared (X2)/Fisher′s exact with one degree of freedom. Chi-
squared (X2) and Fisher′s exact test where appropriate, were used to test homogeneity in alleles 
and genotypes among the participant groups. The same tests were used to determine whether 
genotypes influenced other categorical phenotypes such as neurocognitive status and 
haemoglobin. A P<0.05 was considered statistically significant. The correlation between 
CD4+ T-cell counts with genotypes and risk to neurocognitive impairment were analysed 
using Kruskall-Wallis and Wilcoxon ranking tests respectively. Differences in demographic 
and clinical characteristics between the infected and uninfected were calculated using the X2 
test for categorical data and analysis of variance (ANOVA) for continuous variables. Pairwise 
Linkage disequilibrium (LD) analyses between loci located on the same gene was carried out 
using SHEsis (Li et al. 2009). Lewontin's D′value and r
2
 were used to quantify the level of LD 
ranging from zero for independence to 1 for complete co-inheritance. Haplotypes were 
inferred using the expected maximisation algorithm. The bulk of the statistical analyses were 
done using Stata 11.2 (StataCorp LP, Texas USA) except where SHEsis is indicated as the 














3 CHAPTER THREE: RESULTS 
3.1 Demographic features 
A total of 116 children met the inclusion criteria and were enrolled in the study. Of these, 34 
(29%) were HIV-exposed and HIV-infected (exposed infected; EI) while 82 (71%) were HIV- 
negative controls comprising of 39 (34%) HIV-exposed (exposed but uninfected; EU) and 43 
(37%) not exposed to HIV (unexposed and uninfected; UEUI). Of the 116 blood samples, 106 
(91%) had DNA successfully extracted and formed part of the subsequent genotyping study 
(Figure 2.1). Table 3.1 is a summary of the demographic features and common morbidities 
recorded among the participants. There were no significant differences observed between the 
EU and UEUI groups (appendix D) so the two were combined to form the HIV-uninfected and 
compared to the HIV-infected (EI) group as shown in Table 3.1. HIV-uninfected children 
were significantly taller and weighed more than the HIV-infected. However, body mass index 
(BMI) did not differ significantly with HIV status despite the HIV-infected group having more 
underweight individuals. There were a higher proportion of children with low Hb in the HIV-
infected group compared to the HIV-uninfected group (20% v 11%) although the difference 
was not significant. Occurrence of morbidities was generally higher among HIV-infected 
children compared to the HIV-uninfected with differences of 10% or more in all five clinical 













Table 3.1: Demographic and clinical characteristics of study participants 
Characteristics HIV-infected (EI)   HIV-uninfected 
(EU+UEUI) 
 Odds Ratio P-value 
Mean age in years 
±Stdev (range) 
 8.22 ±0.57 (7.25-9.08 8.43 ±0.55 (7.5-9.08)  N/A  0.28 
     
Mean height in cm 
±Stdev (range) 
117.11 ±6.22 (109-131) 120.37 ±6.00 (108-134)  N/A 0.03 
     
Mean weight in kg 
±Stdev (range) 
20.31 ±1.99 (17-24) 22.35 ±3.01 (15-31)  N/A 0.005 
     
Mean head circum in 
cm ±Stdev (range) 
51.14 ±1.57 (49-54) 51.37 ±1.2 (48-54)  N/A- 0.48 
     
Body mass index n=22 n=62   
Normal (5-85%) 18 (0.82) 55 (0.89) 1.00  
Underweight (<5%) 4 (0.18) 7 (0.11) 1.75 (0.33-7.80) 0.41 
     
Sex n=34  n=72     
Female 20 (0.59) 36 (0.50)  1.00 0.48 
Male 15 (0.41) 36 (0.50) 0.75 (0.31-1.82)   
     
Haemoglobin n=20 n=65    
Normal (11-16g/dL) 15 (0.75) 58 (0.89) 1.00  
Low (<11g/dL)  4 (0.20)  7 (0.11) 2.07 (0.39-9.36)  0.28 
High (>16g/dL) 1 (0.05) 0 (0.00)   
     
Morbidities  n=24  n=72     
Diarrhoea         
No 16 (0.67) 59 (0.82)  1.00   
Yes 8 (0.33) 13 (0.18) 2.27 (0.68-7.13) 0.12 
Ear Discharge         
No 20 (0.83) 67 (0.93)  1.00   
Yes 4 (0.17) 5 (0.07) 2.68 (0.47-13.6) 0.16 
Vomiting         
No 18 (0.75) 61 (0.85)  1.00   
Yes 6 (0.25) 11 (0.15) 1.85 (0.48-6.37)  0.28 
Cough         
No 12 (0.50) 44 (0.61)  1.00   
Yes 12 (0.50) 28 (0.39) 1.57 (0.55-4.41) 0.34 
Fever         
No 10 (0.42) 43 (0.60)  1.00   














3.2 Genomic DNA quantification and integrity 
After DNA was extracted from blood in preparation for genotyping as described in the method 
section 2.2, DNA yield was measured using spectrophotometry and 106 (91%) samples had 
detectable DNA with concentrations averaging 79.04 ng/μl (range; 3.32 to 290.68 ng/μl). Five 
percent of the samples had less than 20ng/µl DNA. DNA integrity check using gel 
electrophoresis showed that for all the 106 samples, intact DNA was successfully extracted. 
The genomic DNA was used to determine variation in selected HIV/AIDS restriction genes. 
3.3 Genotyping for single nucleotide polymorphisms 
As part of genotyping assay designing, primers were designed using bioinformatics tools as 
described in the methods section 2.3.1. Nine pairs of PCR primers were designed and 
successfully amplified DNA fragment flanking CX3CR1 839C>T, RANTES -403G>A, 
APOBEC3G -571G>C, APOBEC3G -90C>G, APOBEC3G 197193T>C (197T>C), 
APOBEC3G 199376C>G (199C>G), MBL2 170G>A SNPs and MBL2 promoter and exon 1 
regions. In addition, seven SNaPshot® primers were designed for genotyping of the following 
SNPs; RANTES -403G>A, APOBEC3G -571G>C, APOBEC3G 197T>C, APOBEC3G 
199C>T, MBL2 -595G>A, MBL2 -221C>G and MBL2 +4C>T. Despite careful designing of 
primers, PCR reactions had to be optimised for successful amplification of DNA fragments. 
Of the 14 PCRs that were successfully optimised with annealing temperatures ranging from 
55˚C to 63˚C, additional Mg
2+ 
was adjusted only for two assays, APOBEC3G 557A>G and 
SDF1 801G>A which required 0.5mM and 1.0mM, respectively. Five percent dimethyl 
sulfoxide (DMSO) was also added to the two reactions, APOBEC3G 557A>G and SDF1 
801G>A to enhance amplification. Post PCR genotyping techniques used included restriction 













Figures 3.1, 3.2, 3.3 and 3.4 show examples of PCR, RFLP, SNaPshot® and Sanger chain 









Figure 3.1: A 2% agarose gel showing a representative PCR. The picture shows a 355bp 
fragment of the CX3CR1 gene flanking the 839C>T (rs3732378) SNP amplified using PCR. 






Figure 3.2: 2% agarose gel electrophoresis showing a representative RFLP. The CCR2 
190G>A (rs17141036) SNP was genotyped using BseGI enzyme restriction. The 190A allele is 
digested into two fragments whilst the 190G remains undigested (Method described by Martinson 















Figure 3.3: Electrophoregram illustrating genotyping by DNA sequencing. Each peak 
represents a nucleotide in the DNA sequence and the black text indicates the allelic variants at a 
polymorphic site.  
  
 
Figure 3.4: Electrophoregram illustrating genotyping by SNaPshot®. The blue and green peaks 














3.4 Baseline allele frequencies and their comparison to other populations 
After genotyping for variants in six HIV/AIDS restriction genes CCR2, CX3CR1,SDF1 
(CXCL12), RANTES (CCL5), APOBEC3G (APOBEC3G) and MBL2, baseline frequencies in 
the Zimbabweans were calculated using the combined HIV-uninfected group (EU+UEUI). We 
report frequencies for the following minor alleles in the Zimbabwean population; CCR2 190A 
(16%), CX3CR1 745A (9%), CX3CR1 839T (1%), SDF1 801A (2%), RANTES In1.1C (20%), 
RANTES -403A (44%), APOBEC3G 557G (40%), APOBEC3G -90C (32%), APOBEC3G -
571C (12%), APOBEC3G 197C (38%), APOBEC3G 199G (6%), MBL2 -595A (0.02), MBL2 
170A (23%), MBL2 -221C (12%), and MBL2 +4C (46%) (Table 3.2). To our knowledge all or 
most of these variants are being reported for the first time in the population. All SNPs 
conformed to the Hardy-Weinberg Equilibrium in the HIV uninfected group used in 
calculation of baseline allele frequencies (EUI + UEUI). 
The frequencies of the alleles in our study cohort were compared to six other populations 
published on HapMap and NCBI dbSNP databases. The populations include the Yoruba of 
Ibadan Nigeria (YRI), African ance try in Southwest USA (ASW), Luhya in Webuye, Kenya 
(LWK), Maasai in Kinyawa, Kenya (MKK), Han Chinese in Beijing (HCB) and the Utah 
residents with Northern and Western European ancestry (CEU). Table 3.2 shows the minor 
allele frequencies in the Zimbabwean population and how they compare to the other 
populations. The prevalence of minor alleles in our study population closely resembled that of 
the YRI, ASW and LWK populations because they are all of African origin. However, there 
were exceptions for example the MBL2 -221G allele frequency had borderline significance for 
difference between the YRI (19%) and this Zimbabwean group (11%) (P=0.05). Another 
MBL2 variant, 170A was significantly lower in the LWK (15%) compared to Zimbabweans 













Table 3.2: Comparison of allele frequencies between the HIV-uninfected (EUI+UEUI) group 
and other populations published on HapMap and NCBI dbSNP databases 
Minor Allele Current 
study  
YRI LWK MKK ASW HCB CEU 
CCR2 190A 
(rs17141036A) 





























0.44 0.43 0.48 0.42 
 












0.32 0.44 NA NA NA N/A 0.32 
A3G 197C 
(rs3736685C) 










0.12 0.04 NA NA NA N/A 0.10 
A3G 199G 
(rs2294367G) 


















0.16 0.14 0.20 
P=0.043 
0.15 0.22 
MBL2  +4C 
(rs7095891C) 








Key: A3G- APOBEC3G, Zim-Zimbabweans; YRI-Yoruba of Ibadan, Nigeria, LWK-Luhya of 
Webuye,Kenya, MKK-Masaai of Kinyawa, Kenya, ASW-African ancestry in Southwest, USA, HCB- 
Han Chinese in Beijing, CEU- Utah residents with Northern and Western European ancestry.                                                     















In addition, two variants, MBL2 -221G and APOBEC3G 197C showed statistically significant 
differences between the ASW (20% & 31%, respectively) and our study population (11% & 
42%, respectively). We also observed that the MKK genetic profile seemed to drift much 
more from the Zimbabwean compared to the other populations of African origin (YRI, LWK 
and ASW). Five out of the ten (50%) allele frequencies that were compared between the MKK 
and our study population showed statistically significant differences. As expected, the Asian 
and Caucasian populations (HCB and CEU respectively) were largely different from the 
Zimbabwean population. Eight out of 13 (62%) and 10 out of 14 (71%) variants in HCB and 
CEU respectively were significantly different from our study population. With baseline allele 
frequencies now established, distribution of genotypes was compared between HIV EI and EU 
groups to determine possible association between genetic variation and risk of HIV infection.  
3.5 Genetic polymorphism and their association with HIV status  
3.5.1 Genetic polymorphism of chemokines receptor genes CCR2 and CX3CR1 
Three SNPs (CCR2 190G>A, rs17141036; CX3CR1 745G>A, rs3732379; CX3CR1 839T>C; 
rs3732378) on two genes encoding for chemokine receptors CCR2 and CX3CR1 were 
genotyped using PCR-RFLP. Their genotype frequencies in the HIV EI and EU groups and 
their measures of association with HIV infection are shown in Table 3.3. The heterozygous 
CCR2 190G/A genotype when compared to the 190G/G genotype was significantly associated 
with reduced risk of infection when compared between the HIV EI (15%) and EU (39%) with 
an odds ratio of 0.27 (95% CI: 0.07-0.97; p=0.02). However, the 190A/A genotype appeared 
more in the HIV exposed infected (EI) children (11.8%) compared to the HIV exposed 













There were no significant differences observed between the EI and EU groups with a 
dominant model for the 190A allele. Genotyping of the two non-synonymous SNPs CX3CR1 
745G>A and CX3CR1 839C>T (T280M) showed the homozygous 745A/A genotype occurred 
more frequently in the EI (10%) compared to the EU (3%) but the difference was not 
statistically significant.  Due to the low frequency of the 839T, the 839T/T genotype was not 
observed in the Zimbabwean population.   
3.5.2 Genetic polymorphism of chemokine genes RANTES and SDF 1 
Frequencies of SDF1 801G>A, RANTES -403G>A and RANTES In1.1T>C genotypes were 
compared between HIV EI and EU children to determine the relationship between genetic 
variants and HIV infection (Table 3.3). A higher frequency of the homozygous -403A/A 
genotype was observed in the HIV exposed infected (17%) compared to the HIV exposed 
uninfected (12%) but the difference was not significant. No association was observed between 
HIV infection and variants of the SNPs, SDF1 801G>A, RANTES -403G>A and RANTES 
In1.1T>C. Since the genotypes resulting from the In1.1T>C and -403G>A SNPs did not show 
significant differences in distribution among the HIV groups individually their co-inheritance 























Table 3.3: Frequency and distribution of chemokine and chemokine receptor genotypes and 
their association with HIV status 
GENOTYPES  EI EU UEUI  OR (95% CI) EI v EU 
p-value 
CCR2 190G>A  
(rs17141036) 
n=34 n=36 N=36     
190G/G 25 (0.74) 21 (0.58) 27 (0.75)  1.00   
190G/A   5 (0.15) 14 (0.39)   8 (0.22)  0.27 (0.07-0.97) 0.02 
190A/A   4 (0.11)   1 (0.03)   1 (0.03)  4.67 (0.42-236) 0.14 
            
CX3CR1 745G>A 
(rs3732379) 
n=31 n=36 n=36     
745G/G 24 (0.77) 29 (0.81) 31 (0.86)  1.00  
745G/A   4 (0.13)   6 (0.17)   5 (0.14)  0.74 (0.14-3.53) 0.67 
745A/A   3 (0.10)   1 (0.03)   0 (0.00)  3.75 (0.28-202) 0.23 
            
CX3CR1 839C>T 
(rs3732378) 
n=31 n=36 n=36     
839C/C 31 (1.00) 36 (1.00) 35 (0.97)  N/A 1.00  
839C/T   0   0    1 (0.03)  N/A N/A 
            
SDF1 801G>A   
(rs1801157) 
n=33 n=36 n=36     
801G/G 31 (0.94) 35 (0.97) 35 (0.97)  1.00   
801G/A   2 (0.06)   1 (0.03)   0 (0.00)  2.26 (0.11-136)  0.50 
801A/A   0    0 (0.00)   1 (0.03)  N/A  N/A 
      
RANTES In1.1T>C 
(rs2280789) 
n=34 n=36 n=35     
In1.1T/T 19 (0.56) 20 (0.56) 23 (0.66)  1.00  
In1.1T/C 14 (0.41) 16 (0.44) 11 (0.31)  0.88 (0.30-2.51)  0.78 
In1.1C/C   1 (0.03)   0 (0.00)   1 (0.03)  N/A  0.30 
            
RANTES -403G>A 
(rs2107538) 
n=33 n=36 n=36     
-403G/G   7 (0.21) 8 (0.22) 11 (0.31)  1.00  
-403G/A 22 (0.67) 22 (0.61) 21 (0.58)  1.27 (0.43-3.84) 0.63 
-403A/A   4 (0.12) 6 (0.17)   4 (0.11)  0.74 (0.14-3.5)  0.67 
Key: EI-HIV exposed infected, EU-HIV exposed uninfected, UEUI- HIV unexposed, N/A- non-













Haplotype formation and linkage disequilibrium (LD) between the RANTES In1.1T>C and -
403G>A were calculated using SHEsis online package (Li et al. 2009). For correct 
approximation of LD between In1.1T>C and -403G>A variants in the population, the HIV-
uninfected group comprising of HIV-exposed and unexposed children (EU+UEUI) was used 
to calculate the LD. The SHEsis program uses the expectation maximisation algorithm to 
infer haplotypes from provided frequencies. Haplotype frequencies were compared between 
the EI children and the combined EU+UEUI groups. Table 3.4 is a summary of the 
haplotypes constructed between RANTES In1.1T>C and -403G>A allelic variants, their 
distribution between the two groups and measures of association. All four expected 
haplotypes were observed in EI and EI+UEUI but the In1.1-403 (C-G) haplotype which is the 
combination of two RANTES down-regulating alleles made up only 2.4% and 1% of the EI 
and EU+UEUI, respectively. No statistically significant differences in haplotype frequencies 
between the HIV-infected and HIV-uninfected were observed. LD analysis (Figure 3.5) 
showed that the In1.1C allele is in weak disequilibrium with the -403A (r2 =0.277, p<0.0001). 
Table 3.4: Frequency and distribution of RANTES haplotypes between HIV infected and 
uninfected groups 
Haplotype EI (n=66) EU+UEUI (n=136) OR (95% CI) P-value 
In 1.1T>C -403G>A     
T G 34 (0.53) 78 (0.56) 0.90 (0.50-1.64) 0.74 
T A 17 (0.25) 34 (0.24) 1.07 (0.55-2.11) 0.84 
C A 13(0.20) 28 (0.19) 1.08 (0.52-2.24) 0.85 
C G   2 (0.02)   1 (0.01) 4.22 (0.21-250) 0.21 














Figure 3.5: LD plot of RANTES SNPs, -40G>A and In1.1T>C. The number in the middle of the 
box shows the r2 value expressed as a percentage. 
3.5.3 Polymorphism in innate immune system genes 
3.5.3.1 APOBEC3G polymorphism 
We genotyped five APOBEC3G (APOBEC3G) SNPs including 557A>G (rs8177832), -
571G>C (rs5757463), -90C>G (rs5757463), 197T>C (rs3736685) and 199C>G (rs2294367) 
and compared their genotype frequencies between HIV EI and HI EU children to determine 
possible association between genetic variants and HIV infection. Table 3.5 shows the 
distribution of APOBEC3G variants in EI and EU children and the measures of association 
with HIV status. Although all the SNPs in the APOBEC3G were polymorphic the -571C/C 
and 199G/G genotypes were not observed in the whole study group and among EI children, 
respectively. The APOBEC3G 557G/G (H186R) genotype occurred more frequently in EI 
children (59%) compared EU children (47%) but the difference was not significantly 
significant. None of the APOBEC3G variants investigated in this study was individually 
associated with risk of HIV infection. Therefore the possible effect of co-inheritance of 













Table 3.5: Frequency and distribution of APOBEC3G and MBL2 genotypes and their 
association with HIV status 
GENOTYPES HIV EI HIV EU UEUI OR (95% CI) P-value 
EI v EU 
A3G 557A>G (rs8177832)  n=32 n=36  n=36     
557A/A   9 (0.28) 12 (0.33) 15 (0.42) 1.00  
557A/G 19 (0.59) 17 (0.47) 16 (0.44) 1.63 (0.56-4.7) 0.32 
557G/G   4 (0.13)   7 (0.19)   5 (0.14) 0.59 (0.11-2.66) 0.44 
            
A3G -90C>G (rs5750743)  n=32 n=36 n=36     
-90G/G 16 (0.50) 17 (0.47) 16 (0.44) 1.00   
-90C/G 14 (0.42) 17 (0.47) 15 (0.42) 0.87 (0.30-2.52)  0.77 
-90C/C   2 (0.06)   2 (0.06)   5 (0.14) 1.13 (0.08-16.50)  0.90 
      
A3G 197T>C (rs3736685) n=33  n=36  n=36     
197T/T   9 (0.27) 13 (0.36) 16 (0.44) 1.00  
197T/C 20 (0.61) 16 (0.44) 15 (0.42) 1.92 (0.67-5.61)   0.18 
197C/C   4 (0.12)   7 (0.19)   5 (0.14) 0.57 (0.11-2.56)  0.41 
            
A3G 199C>G (rs2294367) n=31 n=32  n=34     
199C/C 29 (0.94) 30 (0.94) 29 (0.85) 1.00   
199C/G   2 (0.06)   1 (0.03)   5 (0.15) 2.07 (0.10-126)  0.55 
199G/G   0 (0.00)   1 (0.03)   0 (0.00) N/A  0.32 
      
A3G -571G>C (rs5757463) n=30 n=31  n=36     
-571G/G 23 (0.77) 28 (0.90) 23 (0.64) 1.00   
-571G/C   7 (0.23)   3 (0.10) 13 (0.36)  2.84 (0.56-18.63)  0.15 
      
MBL2 -595G>A (novel) n=32 n=36 n=36   
-595G/G 30 (0.94) 34 (0.94) 35 (0.97) 1.00  
-595G/A   2 (0.07)   2 (0.06)   1 (0.03) 1.13 (0.08-17.32) 0.90 
      
MBL2 -221C>G (rs7096206) n=32 n=36 n=36   
-221G/G 23 (0.73) 27 (0.75) 28 (0.78) 1.00  
-221C/G   9 (0.27)   9 (0.25)   8 (0.22) 1.17 (0.34-3.97) 0.77 
      
MBL2 170G>A (rs1800451G) n=32 n=36 n=36   
170G/G 19 (0.59) 21 (0.58) 20 (0.56) 1.00  
170G/A   9 (0.28) 13 (0.36) 16 (0.44) 0.69(0.22-2.17) 0.48 
170A/A   4 (0.13)   2 (0.06) 0  2.43(0.32-28.34) 0.31 
      
MBL2 +4C>T (rs7095891) n=32 n=36 n=36   
+4T/T 11 (0.34) 11 (0.31) 13 (0.36) 1.00  
+4C/T 12 (0.38) 21 (0.58) 12 (0.33) 0.42 (0.14-1.26) 0.09 
+4C/C   9 (0.28)   4 (0.11) 11 (0.36) 3.0 (0.72-14.59) 0.08 














Haplotypes in the APOBEC3G gene with respect to -571G>C, -90C>G, 557A>G, 197T>C 
and 199C>G SNPs were inferred using SHEsis online software (Li et al. 2009). Haplotype 
frequencies were compared between the HIV-infected children and the HIV-uninfected. 
Table 3.6 shows the haplotypes observed in the HIV-infected and uninfected groups and their 
frequencies. Haplotype C-G-G-C-C (number 7 in Table 3.6) was present in 6% of the HIV-
infected children but absent among the HIV-uninfected (P=0.007). In contrast, haplotypes C-
C-A-T-C (number 5) and G-G-A-T-G (number 6) were observed in 4% of the HIV-
uninfected group each but none in the HIV-infected but the differences were not statistically 
significant. To determine the inheritance patterns of APOBEC3G SNPs in the population, 
pair-wise linkage disequilibrium was calculated in the HIV uninfected group using the 
correlation coefficient, r
2 
using SHEsis online package. Figure 3.6 is an LD plot showing the 
results of the pair-wise LD analysis.  The strongest LD was observed between 557G and 
197C (r
2
=0.83) while the rest were in weak LD with r
2 
<0.2.  
Table 3.6: Haplotype formation with respect to SNPs on the APOBEC3G gene 
 -571G>C -90C>G 557A>G 197T>C 199C>G HIV-pos HIV-neg P-value 
Hap 1 G G G C C 18 (0.31) 44 (0.34) 0.68 
Hap 2 G G A T C 18 (0.30) 26 (0.20) 0.13 
Hap 3 G C A T C 10 (0.17) 28 (0.22) 0.40 
Hap 4 C G A T C   3 (0.05)   7 (0.06) 0.72 
Hap 5 C C A T C   0   5 (0.04) 0.11 
Hap 6 G G A T G   0    5 (0.04) 0.13 
Hap 7 C G G C C   4 (0.06)   0  0.007 
Hap 8 G C G C C   2 (0.04)   3 (0.02) 0.56 















Figure 3.6: Linkage disequilibrium plot of APOBEC3G variants. The boxes show the r2 for LD 
between two SNPs expressed as a percentage. The pink and red boxes indicate where minor alleles are 
in LD and the darker the box, the stronger the LD. 
3.5.3.2 Polymorphism in the MBL2 gene 
After sequencing the promoter and exon 1 of MBL2 gene using Sanger chain termination 
sequencing as described in the methods section, 12 polymorphic sites were detected 
comprising of one novel SNP and 11 previously reported SNPs which included a multiple 
base deletion. Table 3.7 shows the polymorphisms detected in the sequenced region and their 
genotype and minor allele frequencies.  We report a novel G>A variation at position -595 
upstream of the exon 1 start site (MBL2 -595G>A) that has not been previously reported 
(Figure 3.7). Two out of the 26 samples sequenced, two carried the heterozygous -595G/A 














To confirm the frequency of the novel SNP, a SNaPshot® assay was designed to genotype all 
samples in our study cohort (n=106) and it was observed that the -595A variant occurred with 
a frequency of 3% and still no -595A/A homozygotes were observed. The -595G>A genotype 
frequencies were not significantly different between HIV-exposed infected (EI) and exposed 
uninfected (EU) (Table 3.5). Functional analysis of -595G>A variants done using a predictive 
bioinformatics software called TFSearch (Heinemeyer et al. 1998) showed that the MBL2 -
595G>A position does not carry any transcription factor binding site regardless of the 
presence of G or A allele.  
Table 3.7: SNPs detected by DNA sequencing of the MBL2 gene promoter and exon 1 
regions. 
SNP N.t change n F wt/wt* wt/mt* mt/mt* MA (Freq) 
Novel -595G>A 104a  99 (0.93) 5 (0.07) 0  A (0.02) 
rs11003125 -550C>G 28  27 (0.96) 1 (0.04) 0  G (0.02) 
rs7100749 -435G>A 26 2 22 (0.85) 4 (0.15) 0  A (0.08) 
rs11003124 -428A>C 28    6 (0.21) 10 (0.36) 12 (0.43) C (0.39) 
rs7084554 -349A>G 23 5   6 (0.26) 6 (0.26) 11 (0.48) A (0.39) 
rs45560739 -328AGAGAA/del 23 5   8 (0.33) 5 (0.21) 11 (0.46) AGAGAA 
(0.44) 
rs35236971 -245G>A 21 7 19 (0.90) 2 (0.10) 0  A (0.05) 
rs7096206 -221C>G 104a  0  26 (0.25) 78 (0.75) C (0.12) 
rs67990116 -111A>T 21 7 19 (0.90) 2 (0.10) 0  T (0.10) 
rs11003123 -70C>T 23 5   7 (0.31) 7 (0.30)   9 (0.39) C (0.46) 
rs7095891 +4C>T 104a  24 (0.23) 45 (0.43) 35 (0.34) C (0.45) 
rs5030737 154C>T 26 2 26 (1.00) 0 0 T (0) 
rs1800450 161G>A 26 2 26 (1.00) 0 0 A (0) 
rs1800451 170G>A 104a  60 (0.58) 38 (0.36)   6 (0.06) A (0.24) 
Key: N- total number of samples genotyped, F- failed samples, N.t- nucleotide, wt-wild type allele, 
mt- mutant allele, MA (Freq) - minor allele frequency.                                                                                                                                    
a the SNPs were further genotyped in the samples remaining after sequencing.                                          
*wt= refers to the starting allele as indicated in the nucleotide base substitution column and      















Of the eleven previously reported SNPs detected from the sequencing, three are part of a 
battery of MBL2 polymorphisms that have been linked with variation in MBL protein levels 
and various diseases including HIV. These SNPs include -221C>G (-221X/Y) in the promoter 
region, +4C>T (+4P/Q) in the non-coding 5′-UTR and 170G>A (G57E) in the coding region 
of exon 1. Two other exon 1 SNPs that have been linked with HIV restriction, 154C>T 
(R52C) and 161G>A (G54E) were monomorphic during sequencing and therefore not 
pursued any further. The SNPs -221C>G, +4C>T and 170G>A were genotyped in the 
samples that had not been sequenced using other genotyping techniques as described in the 
methods chapter. The genotype and allele frequencies distribution for the SNPs are shown in 
Tables 3.2 and 3.5 respectively.  
 
 
Figure 3.7: Electrophoregram showing the novel MBL2 -595G>A SNP. The top panel shows 
the G allele whilst the bottom panel shows the heterozygous A/G genotype at the position highlighted 















In the MBL2 5-UTR, the homozygous +4C/C genotype occurred more in HIV EI children 
(28%) compared to the EU (11%) with near borderline significance under a recessive model 
(OR=2.9 (95% CI, 0.70-14.59), P=0.09). In the promoter region, SNP -221C>G showed a 
higher frequency of heterozygous -221C/G genotype in HIV EI children (27%) compared to 
the EU (25%) although the differences were not statistically significant. Despite the presence 
of up to 20% of heterozygous -221C/G genotypes, the homozygous -221G/G genotype was 
not observed in the whole study population. In exon 1, the distribution of 170G>A genotypes 
between EI and EU groups was not significantly different.  
MBL2 genotypes were combined and their frequencies compared between HIV-exposed 
infected (EI) and HIV-exposed uninfected (EU) children to determine if co-occurrence of 
variants had a possible effect on HIV infection. The MBL2 -221G/G-+4C/T (Y/P-Y/Q) 
genotype combination was associated with reduced risk of HIV infection compared to other -
221C>G-+4C>T genotypes combinations because its frequency was significantly lower in the 
EI group (22%) compared to the EU (44%) group (OR=0.32, 95%C.I; 0.09-1.04, P=0.03). In 
addition, the +4C/C-170G/A (P/A-P/O) genotype combination was observed in 9% of EI 
children but not the HIV exposed uninfected (P=0.06)       
Pair-wise LD was calculated for all SNPs detected in the MBL2 promoter and exon 1 regions. 
Figures 3.8 is an LD plot showing the level of LD between each pair of SNPs. LD is strongest 
between the MBL2  -328del and -349G  alleles (r2 =1) which are located 21 bases apart in the 
genome. Inspection of the sequences showed that the homozygous -328del/del almost always 
occurs with the homozygous MBL2-349G/G whilst the heterozygotes are also inherited 














Figure 3.8: Linkage disequilibrium plot of MBL2 SNPs. The plot shows pair-wise LD of MBL2 
variants in the promoter and exon1. The numbers in the boxes are percentage r2 values indicating 
strength of LD.  
Haplotype formation with respect to the -221C>G, +4C>T and 170G>A SNPs was also 
investigated. Seven haplotypes were observed, five in both HIV-infected and HIV-uninfected 
groups and the other two appearing in one of the HIV groups but not in the other. Table 3.8 
shows the frequencies and distribution of the haplotypes between the HIV-infected and HIV-
uninfected children. We observed a haplotype that has not been previously reported, C-C- A 
(X-P-O or haplotype 6 in Table 3.8) in the HIV-infected group. This however, was found in 


















Table 3.8: Haplotype formation with respect to SNPs in the MBL2 gene and their comparison 
between HIV infected and uninfected children 
MBL2 haplotypes HIV pos  HIV neg  OR (95% CI)  P-value 
  -221C>G 4C>T 170G>A AN 
Hap 1 G T G YQA 21 (0.33) 52 (0.36) 0.85 (0.46-1.5) 0.62 
Hap 2 G C G YPA 19 (0.30) 42 (0.30) 1.04 (0.55-1.9) 0.90 
Hap 3 G T A YQA 13 (0.20) 26 (0.18) 1.17 (0.56-2.4) 0.68 
Hap 4 C C G YQC   7 (0.10) 13 (0.09) 1.12 (0.42-2.9) 0.81 
Hap 5 G C A XPA   2 (0.03)   6 (0.06) 0.56 (0.10-2.6) 0.51 
Hap 6 C C A XPO   2 (0.04)   0 8.06 (0.91-7.0) 0.08 
Hap 7 C T G XQA   0   3 (0.02) N/A 0.46 
Key: Hap- haplotype, AN- alternative haplotype nomenclature 
     
3.6 Genotype combinations and HIV status 
The effect of single SNPs on HIV transmission or disease progression might be difficult to 
ascertain given the wide range of host proteins involved in the host parasite interaction 
pathways. However, when several pathways are disrupted due to multiple polymorphisms in 
different genes, a notable effect may be exerted. Given this, genotypes of selected SNPs were 
compared between HIV exposed infected (EI) and exposed uninfected (EU) children to 
determine their association with risk of HIV infection (Table 3.9). 
The CCR2 190G/A-CX3CR1 745G/G combination was significantly associated with reduced 
risk of HIV infection compared to other CCR2 190G>A-CX3CR1 745G>A combinations as it 
occurred in 33% of HIV-exposed uninfected children but was not observed in than the EI 
group (P<0.001).  The combination of two homozygous genotypes CCR2 190A/A-CX3CR1 
745A/A was not observed in our study population. Combination between CCR2 190G>A and 













Table 3.9: Genotype combinations and their association with HIV status 
Genotype combination HIV EI HIV EU OR (95% CI) P-value 
CCR2 190G>A v CX3CR1 745G>A N=31 N=36   
190G/G + 745G/G 22 (0.71) 17 (0.47) 1.00 0.037 
190G/G + 745G/A 1 (0.03) 3 (0.08) 0.38 (0.0-5.06) 0.394 
190G/G + 745A/A 1 (0.03) 1 (0.03) 1.2 (0.01-96.77 0.90 
190G/A + 745G/G 0 13 (0.33) N/A 0.0002 
190G/A + 745G/A 3 (0.10) 2 (0.0.6) 1.86 (0.20-23.68) 0.501 
190G/A + 745A/A 2 (0.06) 0  N/A 0.17 
190A/A + 745G/G 2 (0.06) 0 N/A 0.17 
     
CCR2 190G>A v A3G 557A>G N=32 N=36   
190G/G + 557A/A 7 (0.22) 5 (0.14) 1.00 0.39 
190G/G + 557A/G 15 (0.47) 11 (0.31) 2.00 (0.67-6.10) 0.1 
190G/G + 557G/G 2 (0.06) 5 (0.14) 0.41 (0.04-2.8) 0.30 
190G/A + 557A/A 0 6 (0.17) N/A 0.015 
190G/A + 557A/G 4 (0.13) 6 (0.17) 0.71 (0.13-3.40) 0.63 
190G/A + 557G/G 1 (0.03) 2 (0.06) 0.55 (0.09-11.11) 0.63 
190A/A + 557A/A 2 (0.06) 1 (0.03) 2.33 (0.11-141) 0.49 
190A/A + 557G/G 1 (0.03) 0 N/A 0.29 
     
CX3CR1 745G>A v RANTES 
In1.1T>C  
N=31 N=36   
745G/G + In1.1T/T 13 (0.42) 17 (0.47) 1.00 0.66 
745G/G + In1.1T/C 10 (0.32) 12 (0.33) 0.95 (0.30-2.98) 0.93 
745GG + In1.1C/C 1 (0.03) 0 N/A 0.28 
745G/A + In1.1T/T 3 (0.10) 3 (0.08) 1.18 (0.15-9.49) 0.85 
745G/A + In1.1T/C 0 3 (0.08) N/A 0.10 
745A/A + In1.1T/T 3 (0.10) 0 N/A 0.056 
745A/A + In1.1T/C 1 (0.03) 1 (0.03) 1.1 (0.01-94.16) 0.91 















Analyses of CCR2 190G>A-APOBEC3G 557A>G genotype combinations revealed that the 
CCR2 190G/A-APOBEC3G 557A/A genotype combination was associated with protection 
against HIV infection as it was observed in 17% of the EU and but none in the EI group 
(P=0.015). The CCR2 190 A/A-APOBEC3G 557A/G combination was not found in the 
whole study population. An attempt to analyse genotype combinations amongst the three 
SNPs CCR2 160G>A, APOBEC3G 557 A>G and CX3CR1 745G>A was not possible 
because of small sample size. However, CX3CR1 745G>A-APOBEC3G 557A>G genotype 
combination analysis showed that the occurrence of CX3CR1 745G/G-APOBEC3G 557G/G 
was notably lower in EI children compared to EU (19.44% v 6.45 %) even though this 
difference was not statistically significant. 
3.7 Genetic polymorphism and laboratory markers of disease progression 
Possible association between genetic polymorphism and the following indicators of HIV 
disease progression; CD4+ T-cell counts, haemoglobin (Hb) and BMI was investigated. 
CD4+ T-cell counts in HIV-infected children were categorised into “low” for figures below 
350cells/mm
3 
and “normal” for counts above 350cells/mm
3
. This grouping was done with the 
intention to determine association between genetic variation and CD4+ T-cell count status. 
However, this proved difficult as there were only three children with a CD4+ T-cell count 
below 350cells/mm
3
. When the Kruskall-Wallis equality of proportion rank test was 
alternatively used to calculate differences in CD4+ T-cell counts among HIV-infected 
children with different genotypes, no significant differences in CD4+ T-cell count median 














Among the indicators of disease progression investigated was haemoglobin (Hb). To 
determine if genetic polymorphism has a role to play in preservation of haemoglobin levels, 
we compared Hb level in individuals carrying different genotypes (Appendix C). Hb was 
grouped into low and normal using 11g/dl-16g/dl as the normal range in children. The 
APOBEC3G -571G/C genotype was associated with a low Hb (Hb<11g/dl) compared to the 
homozygous APOBEC3G -571G/G regardless of HIV status (P=0.01). The frequency of 
RANTES -403G/A genotype was higher in individuals with low Hb (80%) compared to those 
with normal Hb (57%). No association was observed between Hb levels and the rest of the 
SNPs investigated in this study. BMI also did not show any association with genetic variants 
investigated in this study. 
3.8 Genetic polymorphism and neurocognitive function 
Neurocognitive deficits are common among HIV-infected individuals with more aggravating 
effects on children compared to adults. In this study, possible association between genetic 
variation and neurocognitive function as determined by the McCarthy Scale of Children‟s 
Abilities (MSCA) among HIV-infected and HIV-uninfected children aged seven to nine years 
was investigated. The MSCA neurocognitive index scores were available for 21 HIV-exposed 
infected (EI) and 64 HIV-uninfected (EU+UEUI) children only at the time of writing as they 
were administered as part of a bigger study. Children were divided into unimpaired and 
impaired using cut-off values for each neurodevelopmental attribute as described in the 
methods. The results are shown in Table 3.10 below. The number of children falling below 
cut-off was generally higher in the HIV-infected compared to the HIV-uninfected for all four 
categories assessed using the MSCA which are; verbal, perceptive performance, quantitative 













The highest number of children falling below cut-off was in the quantitative index score 
category followed by perceptive and the verbal category had the least. CD4+ T-cell counts 
were compared between HIV-positive children falling below and above the cut-off values for 
all neurocognitive attributes but no significant differences were observed. 
Table 3.10: Neurocognitive index scores in HIV infected and uninfected children 
Attribute HIV-infected HIV-uninfected OR (95% C.I) P-value 
     
General CIS     
>68 14 (0.67) 53 (0.83) 1.00  
<68 7 (0.33) 11 (0.17) 2.41 (0.66-8.30) 0.12 
     
Verbal CIS     
>30 17 (0.81) 58 (0.91) 1.00  
<30 4 (0.20) 6 (0.09) 2.27 (0.42-10.82) 0.23 
     
Perceptive CIS     
>30 14 (0.67) 54 (0.84) 1.00  
<30 7 (0.33) 10 (0.16) 2.7 (0.72-9.50) 0.08 
     
Quantitative CIS     
>30 11 (0.52) 40 (0.63) 1.00  
<30 10 (0.48) 24 (0.37) 1.52 (0.49-4.59 0.4 
Key: CIS- cognitive index score 
To determine possible association between genetic variation and neurocognitive function, 
genotype frequencies were compared between cognitively-impaired and unimpaired groups 
of children for each of the four categories (Table not shown). Because HIV has been linked 
with neurocognitive deterioration, analysis was done on HIV-infected and HIV-uninfected 
groups separately. In the HIV-infected group, the APOBEC3G -90C/G genotype was 
associated with poor cognitive ability compared to the -90C/C and -90G/G genotypes as it 
occurred more in individuals who had a general cognitive index score (CIS) of 68 and below 













The APOBEC3G -90C/G was also observed more frequently in the verbally (73%) and 
perceptively impaired (71%) compared to the unimpaired (33% and 25%, respectively) but 
the differences were not significant. In addition, the MBL2 170G/A (A/O) genotype was 
significantly associated with high perceptive performance compared to the 170G/G and 
170A/A as its occurrence was significantly higher in the unimpaired group (42%) compared 
to the impaired (0%) with regard to the perspective index score (P=0.046).  
Other genetic variants showed weak association with neurocognitive impairment. For 
example, the RANTES In1.1T/C genotype was observed in 57% of the generally impaired 
HIV-positive children compared to 23% in the unimpaired but difference was not statistically 
significant. Another heterozygous RANTES variant, -403G/A  was more frequent in generally 
impaired HIV positive children (86%) compared to the unimpaired HIV positive group (54%) 
but the difference was also not statistically significant. A fraction of HIV uninfected children 
develop neurocognitive deficits suggesting that etiological agents other than HIV are at play 
and genetic variation maybe one of the factors. Thus, genotype frequencies were compared 
between cognitively impaired and unimpaired children who are HIV-uninfected. 
MBL2 polymorphisms appeared to have a significant contribution to neurocognitive function 
in children in the absence of HIV (Table 3.11). The frequency of the MBL2 +4C/C (P/P) 
genotype was significantly higher in the verbally impaired HIV-uninfected group (50%) than 
the unimpaired (14%) (P=0.03). It was also observed that all verbally impaired children had 
at least one +4C allele. A dominant model of was therefore considered for the +4C allele 
(+4T/C + +4C/C vs +4T/T) and the frequency of +4C carrying genotypes remained 













Another MBL2 promoter region variant -221C/G (X/Y) also occurred more frequently in the 
verbally impaired HIV-negative children (50%) compared to the unimpaired with borderline 
significance (17%) (P=0.057).  The frequency of MBL2 -221C/G genotype was also 
statistically higher in individuals with a general NCI score below cut-off (45%) compared to 
those above (15%) (P=0.02). 
Table 3.11: MBL2 genotypes and their association with verbal and general neurocognitive 
impairment in HIV-uninfected children 
GENOTYPES Verbal cognition P-value General Cognition P-value 
 
 Unimpaired Impaired  Unimpaired Impaired  
MBL2 -595G>A 
(novel) 
      
-595G/G 56 (0.97) 6 (1.0) 1.00 51 (0.96) 11 (1.00) 1.00 
-595G/A 2 (0.03) 0 (0)  2 (0.04) 0  
       
MBL2 -221C>G 
(rs7096206) 
      
-221G/G 48 (0.83) 3 (0.50) 0.092 45 (0.85) 6 (0.54) 0.023 
-221C/G 10 (0.17) 3 (0.50)  8 (0.15) 5 (0.45)  
       
MBL2 170G>A 
(rs1800451G) 
      
170G/G 34 (0.59) 2 (0.33) 0.234 31 (0.58) 5 (0.45) 0.4277 
170G/A 22 (0.38) 4 (0.67) 0.172 20 (0.38) 6 (0.55) 0.3016 
170A/A 2 (0.03) 0 0.644 2 (0.04) 0 0.5127 
       
MBL2 +4C>T 
(rs7095891) 
      
+4T/T 23 (0.40) 0  0.05 20 (0.38) 3 (0.27) 0.5104 
+4C/T 27 (0.46) 3 (0.50) 0.872 25 (0.47) 5 (0.46) 0.9174 


















4 CHAPTER FOUR: DISCUSSION AND CONCLUSION 
Since the discovery of HIV as cause of AIDS in the middle 1980s, it has been noted that the 
virus is heavily-dependent on the host machinery for the completion of its life cycle (Frankel 
et al. 1998). This led to investigations on what role the host might play in facilitating its own 
destruction or mounting a defence against HIV. The observation that some individuals, 
despite constant exposure to HIV either remained uninfected or if infected took much longer 
to develop HIV-associated symptoms even in the absence of antiretroviral therapy pointed to 
a possible role of host genetic variation in HIV infection and disease progression (Fowke et 
al. 1996, Kroner et al. 1994). In this study, we investigated the frequency and distribution of 
genetic variants in six genes; CCR2, CX3CR1, SDF1, RANTES, APOBEC3G and MBL2 in 
HIV-exposed (infected and uninfected) children and HIV unexposed controls and their 
possible association with HIV infection and neurocognitive function. 
The demographic features of the children enrolled showed that HIV-uninfected children were 
significantly taller and weighed more than the HIV-infected indicating possible slowed 
growth due to HIV-related challenges. HIV-infected children are constantly faced with a 
wide range of opportunistic infections and organ damage which may slow their growth 
compared to the uninfected (Owor et al. 2004, Bailey et al. 1999). Body mass index 
calculations also showed HIV-infected children to be underweight compared to the 
uninfected even though the difference was not statistically significant. Occurrence of 
morbidities was generally higher in HIV-infected children compared to the HIV-uninfected 
with differences of 10% or more in all five clinical conditions. This also may be a result of 













However, the focus of the study was to describe human genetic variation and its correlation 
with HIV-infection and neurocognitive function. Baseline allele frequencies for the SNPs 
genotyped were established using the HIV-uninfected group (EU+UEUI). HIV-infected 
children were excluded from baseline frequency calculations because their genetic profile 
may not be representative of the population. For example, if host genetic variation has a role 
in HIV transmission then HIV-infected individuals are likely to carry more of the 
susceptibility alleles compared to the uninfected. The distribution of alleles in the HIV 
negative group of our study population conformed to the HWE for all SNPs studied 
indicating that the group can be correctly used to approximate allele frequencies for the 
population. Allele frequency data forms a baseline for further studies on the effect of genetic 
polymorphism on disease susceptibility, treatment response and disease progression in 
different populations. Distribution of alleles in populations may also be useful in estimating 
disease burden in the different populations.  
After establishing baseline frequencies in the Zimbabwean children, the distribution of 
genotypes between HIV exposed infected (EI) and HIV exposed uninfected (EU) children 
was compared to determine possible association between host genetic variants and risk of 
HIV infection. Our study involved three groups of viral restriction genes which are 
chemokine receptors (CCR2 and CX3CR1), chemokines (RANTES and SDF1) and innate 
















4.1 Chemokine receptor polymorphism and their association with HIV 
infection   
CCR2 is a chemokine receptor and minor HIV co-receptor that is involved in leukocyte 
trafficking during inflammation and several other physiological processes (Palframan et al. 
2001, Cardona et al. 2008). We genotyped the CCR2 190G>A (V64I) SNP and observed a 
frequency of 16% for the 190A allele in the study population which does not differ much 
from what has been observed in other African populations. Studies on Africa populations 
show frequencies ranging from about 13% among black South Africans (Williamson et al. 
2000) to 23% among Kenyans (Anzala et al.1998). The occurrence of the CCR2 190A allele 
has been reported to vary considerably among ethnic groups in the same population as shown 
in Cameroonians where it ranged from 10 to 30% among seven ethnic groups (Ma et al. 
2005). Frequencies of the CCR2 190A allele in Zimbabweans and among other African 
populations are slightly higher than what has been observed in Caucasians (7-10%) 
(Williamson et al. 2000, Struyf et al. 2000). Asian populations show a wide range of CCR2 
190A allele frequencies (1-30%) (Qian et al. 2008, Su et al. 1999) which overlaps with both 
African and Caucasian frequencies. The distribution of CCR2 190A allele among the 
Caucasians, Africans and Asians does not seem to exhibit trends suggestive of the variant‟s 
role in HIV restriction at population level.  
Frequencies of CCR2 190G>A genotypes were compared between HIV-exposed infected and 
HIV-exposed uninfected groups to determine association between variants and risk of HIV 
infection among individuals. We found the CCR2 190G/A genotype frequency significantly 
higher in HIV-exposed uninfected (EU) children compared to the HIV-exposed infected (EI) 













A possible mechanism of protection is that the 190A (64I) allele encodes a protein variant of 
the CCR2 receptor that is able to dimerise with HIV main co-receptor CXCR4 whereas the 
190G (64V) has reduced affinity (Mellado et al. 1999). The dimerization reduces the amount 
of CXCR4 available for HIV binding therefore reducing the chances of HIV entering the cell. 
Surprisingly, neither the homozygous 190A/A genotype nor the 190A allele frequencies were 
significantly different between the HIV EI and EU. However, it has been suggested that the 
190A allele is dominant over the 190G allele (Winkler et al. 1998), thus, the heterozygous 
190G/A may be capable of exerting a full effect even with a single 190A allele. We however, 
did not find statistically significant differences between the EI and EU under the dominant 
model. These observations led to the conclusion that CCR2 190G>A SNPs might not have a 
significant individual role in risk of HIV infection.  
Our observation support reports from two studies among Kenyans and French children where 
no significant differences were observed between HIV-infected and uninfected children 
infants born to HIV-infected mothers in the distribution of the 190A variant (Teglas et al. 
1999, Brouwer et al. 2005). Contrary to our findings, a multicentre study involving Ugandans 
(n=358), Malawians (n=322) and South Africans (n=300) reported an increased risk of HIV 
infection in children homozygous for the 190A/A genotype when compared to 190G/G and 
190G/A genotypes (Singh et al. 2008). The findings of Singh et al., (2008) however may 
have been distorted by the heterogeneous sample drawn from the three countries. In a 
separate study, our research group has demonstrated differences in distribution of genetic 
variants among African populations therefore pooling samples from different countries in 













The chances of infection per child in the multicentre study could not have been the same 
given that Uganda has HIV subtypes A and D predominantly whilst South Africa and Malawi 
have subtype C (Buonaguro et al. 2007).  
HIV subtype C has been shown to be more transmissible compared to both subtype A and D 
(Renjifo et al. 2004). In contrast to Singh et al. (2008), a study among Argentinians reported 
that the CCR2 190A/A genotype was significantly higher in HIV-exposed uninfected 
compared to exposed infected children again supporting a protective role against infection 
(Mangano et al. 2000). Given that CCR2 is a minor HIV co-receptor and its chemotactic roles 
are also executed by alternative pathways, CCR2 190G>A variation may be contributing little 
to the antiviral activity, thus, its role in HIV infection remains a subject of debate. Therefore 
in addition to CCR2, another chemokine receptor gene CX3CR1 was also investigated. 
CX3CR1 is a receptor for fractalkine which also acts as a minor HIV co-receptor (Imai et al. 
1997, Combadiere et al. 1998). The CX3CR1-fractalkine pair is important for leukocyte 
trafficking and chemotaxis during inflammation (Nishimura et al. 2002). Two non-
synonymous SNPs; CX3CR1 745G>A (V249I) and CX3CR1 839T>C (T280M) in the coding 
region of the gene were investigated in this study. We report frequencies of 9% and 1% for 
the 745A and 839T alleles, respectively in Zimbabweans. The occurrence of the 745A allele 
in our study population is lower than what has been reported among Caucasians (20.2%) 
(McDermott et al. 2000) but higher than that in Asian populations (2-5%) (Li et al. 2005); 
(Qian et al. 2008). The 839T allele was also less frequent in our study population compared 
to Caucasians (15%) but comparable to observations among Asians (2%) (Li et al. 2005). The 
high frequency of CX3CR1 variants among Caucasians compared to that among Africans and 













This is because the resultant amino acid alterations (249I and 280M for 745A and 839T, 
respectively) are associated with less efficient binding of CX3CR1 receptors on peripheral 
blood mononuclear cells to ligand fractalkine. This reduces fractalkine-induced chemotaxis 
and therefore weakens the immune response mounted against HIV and other pathogens 
through the pathway (Faure et al. 2000) yet HIV prevalence is much lower in Caucasians 
compared to both Africans and Asians. We therefore speculate that CX3CR1 variants may be 
risk factors for some inflammatory diseases that are more common among Caucasians as 
opposed to HIV/AIDS. For example, CX3CR1 polymorphisms have been implicated in 
conditions like Crohn‟s disease, multiple sclerosis and bronchiolitis in Caucasian populations 
(Brand et al. 2006, Amanatidou et al. 2006, Stojković et al. 2012). 
 There were no significant differences in CX3CR1 745G>A genotype and allele frequencies 
between HIV EI and EU children. This implies that 745G>A variation alone may not have a 
significant role in HIV transmission. Our observations are supported by a study involving 
three sub-Saharan countries, South Africa, Uganda and Malawi where they also did not find 
any association between 745G>A var ation and HIV infection in children born to ART naïve 
mothers (Singh et al. 2008). The same study however, observed that the CX3CR1 745A allele 
was associated with greater risk of HIV infection compared to the CX3CR1 745G in children 
born to infected mothers on ART prophylaxis (Singh et al. 2008). This observation suggests 
that the effect of CX3CR1 745G>A variation on HIV infection might require a minimum 
threshold of other protective mechanisms to be noticed. Not many studies have investigated 
the effect of 745G>A variation on HIV infection in children but a few have reported on adult 
population where no association has been observed (Faure et al. 2000, Suresh et al. 2006). 














CX3CR1 745A and 839T have been shown to be in complete LD in Caucasian and Chinese 
populations (Qian et al. 2008, Faure et al. 2000) which is in contrast to our observation where 
745A and 839T seem to be in complete equilibrium (r
2
=0.001).  Because of the complete LD 
in the populations, 745A and 839T alleles have been studied as haplotype CX3CR1 745-839 
(A-T) and found to be associated with faster HIV disease progression in both adults and 
children (Faure et al. 2000, Brumme et al. 2003, Singh et al. 2005) as explained by the 
resulting reduced chemotactic activity of CX3CR1 described above. In addition to chemokine 
receptors, chemokines have also been implicated in HIV infection therefore two chemokines 
RANTES and SDF1 also formed part this study. 
4.2 Chemokine receptor variants and their association with HIV infection 
RANTES and SDF1 are natural ligands of the major HIV co-receptors CCR5 and CXCR4, 
respectively, thus, are able to inhibit HIV infection by competitively binding to these 
receptors (Bajetto et al. 2001, Choe et al. 1996). The frequency of SDF1 801G>A variants 
varies widely in different populations. We report a frequency of 2% for the SDF1 801A allele 
in the Zimbabwean population. This is comparable to what has been reported among black 
South Africans (1%) and the Yoruba of Ibadan Nigeria (2%) (Williamson et al. 2000); 
dbSNP). In contrast, the SDF1 801A allele occurs at frequencies of between 15% and 30% 
among Caucasians (Williamson et al. 2000, Apostolakis et al. 2005, Wasik et al. 2005). 
Asian populations exhibit a wider range of SDF1 801A allele frequencies, ranging between 















The effects of SDF1 801G>A genotypes on HIV infection in our study population could not 
be determined because of the low frequency of the 801A variant.  The 801A allele makes the 
SDF1 mRNA more stable post transcription, thus, up-regulating the synthesis of the SDF1 
protein. This makes more SDF1 protein available for competitive binding against HIV 
(Winkler et al. 1998). It can therefore be speculated that the differential distribution of the 
SDF1 801A allele between Africans and Caucasians maybe contributing to the higher HIV 
prevalence among Africans compared to Caucasians. However, high frequency of SDF1 
801A in Asians where HIV prevalence is also high casts doubt on its protective effect against 
HIV. HIV is a multifactorial condition hence there might be other underlying factors that 
work in concert with the 801A variant to give its differential role in different settings. 
In contrast to SDF1 801G>A, the two RANTES SNPs (In1.1T>C and -403G>A) genotyped in 
this study were highly polymorphic in the population with minor allele frequencies of 20% 
(In1.1C) and 44% (-403A). The frequency of the RANTES In1.1C allele in our study 
population was lower than what has been observed among Asians (28%) (Qian et al. 2008) 
but higher than that among Caucasians (10%) (Laplana et al. 2012). The occurrence of the 
RANTES -403A allele in Zimbabweans (44%) was lower than that among Caucasians (16%) 
(Ahlenstiel et al. 2005) but comparable to that observed among Asians (40%) (Zhao et al. 
2004). The In1.1T>C polymorphism is located in an intronic regulatory sequence and the 
In1.1C variant is associated with down-regulation of RANTES expression (An et al. 2002) 
resulting in less chemokine to inhibit HIV binding or internalise CCR5 receptors on T -cells, 
thus, favouring HIV infection. The high frequency of the In1.1C allele in Africans and Asians 
may argue for similar susceptibilities to HIV infection in the two populations when compared 













In contrast, RANTES -403A increases expression of RANTES (Liu et al. 1999, Nickel et al. 
2000) thus its presence may reverse the down-regulating effect of RANTES In1.1C.  
When RANTES In1.1T>C and -403G>A genotype frequencies were compared between HIV 
EI and EU groups, there were no significant differences observed. Our results support reports 
among Kenyans where they did not observe any significant differences between HIV exposed 
infected and uninfected in RANTES -403G>A genotype frequencies  (Katz et al. 2010). Not 
much has been reported on the distribution of RANTES variants between EI and EU children 
thus our study attempts to understand the effect of RANTES variants in perinatal HIV 
infection of exposed children. However there are several reports on the association between 
RANTES polymorphism and risk of HIV infection in adults.  
A study among Indians reported that the In1.1T allele was a risk factor for HIV infection but 
did not observe any association between -403G>A variants and HIV transmission (Rathore et 
al. 2008). In contrast to this and our findings, other studies have reported association between 
the RANTES -403A allele and increased risk of HIV infection under different settings 
(McDermott et al. 2000, Ahlenstiel et al. 2005). However, both studies used HIV negative 
controls that had no known history of HIV exposure. There is no general consensus on the 
effect of RANTES polymorphism on risk of HIV infection and our study adds to the growing 
body of conflicting findings. 
The frequency of RANTES haplotypes with respect to In1.1T>C and -403G>A loci did not 
show any significant differences between the HIV EI and EU children. This observation 
suggests the effect of the co-inheritance of RANTES In1.1T>C and -403G>A alleles on the 













In contrast to our findings, An et al. (2002) reported an association between haplotypes 
containing In1.1C and -403A alleles and increased susceptibility to HIV infection among 
African American adults (An et al. 2002). Another study supported the observation that 
RANTES haplotypes may influence risk of HIV infection by reporting association between 
In1.1T-403A containing haplotypes and increased risk of HIV infection among Indian adults 
(Rathore et al. 2008).  
The RANTES In1.1-403 (C-G) haplotype which carries two RANTES down regulating alleles 
was observed at very low frequency in the Zimbabwean population (1%) which is 
comparable to observations in Caucasians, Indians and African Americans where the C-G 
haplotype was not reported (An et al. 2002). The C-G haplotype is rare possibly because it 
carries both RANTES down-regulating variants which results in excessively low levels of 
RANTES protein that might not be able to sustain its multiple roles in the immunity and 
organ development, thus, may be aborted during development. This study also investigated 
genetic polymorphism in two innate antiviral factor genes APOBEC3G and MBL2.  
4.3 Polymorphism in genes encoding innate immune system factors 
4.3.1 APOBEC3G polymorphism 
APOBEC3G is a cytidine deaminase that converts cytidine bases to uracil on the new HIV 
minus strand during reverse transcription (Bishop et al. 2004). This results in multiple G>A 
changes on the HIV DNA sense strand, a process called hypermutation. Hypermutation 
introduces stop codons on the HIV genome which disrupt production of new virions (Zhang 
et al. 2003). This study investigated genetic variation at five APOBEC3G loci and their 













APOBEC3G 557A>G is the most studied of the APOBEC3G SNPs. We report a frequency of 
40% for the 557G allele in the Zimbabwean population which is slightly higher to that 
observed among black South Africans (30%) and African Americans (37%) (An et al. 2004, 
Reddy et al. 2010) but much higher than among Caucasians (<5%) (An et al. 2004) and 
Asians (0%) (Rathore et al. 2008b). The APOBEC3G 557A>G polymorphism results in an 
H186R amino acid change on the APOBEC3G protein that alters its catalytic activity. The 
proposed mechanism is that the polymorphic site is involved in protein-protein interaction 
thus, the 557G (186R) variant leads to poor protein assembly which reduces APOBEC3G‟s 
catalytic functions (Jarmuz et al. 2002, MacGinnitie et al. 1995). In addition to the possible 
effect of the H186R amino acid alteration, APOBEC3G activity is determined by amount of 
the enzyme available in the circulation (Jin et al. 2007, Mariani et al. 2003). Inter-individual 
variation in APOBEC3G level in circulation may be a result of polymorphism in the gene‟s 
promoter region and other regulatory sequences such as those close to splice variants in 
introns. Thus two promoter SNPs APOBEC3G -90C>G and APOBEC3G -571G>C and two 
intron SNPs APOBEC3G 197193T>C (197T>C) and APOBEC3G 199376C>G (199) were 
investigated in this study. 
We report frequencies of 32%, 12%, 42% and 6% for -90C, -571C, 197C and 199G alleles 
respectively in the Zimbabweans. There is limited information on the frequency and 
distribution of these alleles in different populations but this is how our observations 
compared to what has been published on dbSNP, NCBI. The occurrence of the -90C allele in 
our study is lower than that observed among the Yoruba of Nigeria (YRI) (32% v 44%) but 
higher than among Caucasians (4%). The frequency of the -571C was higher among the 














The distribution of APOBEC3G 197C allele frequency was comparable between 
Zimbabweans (42%) and YRI (48%) but higher than that observed among Caucasians (4%) 
and Asians (5%). In contrast to -90C, -571C and 197C alleles whose frequencies were 
generally higher in our study population and other Africans compared to Caucasians, the 
199G allele was more frequent among Caucasians (58%) and Asians (66%) compared to 
what we observed (6%) and that among the YRI (4%). The distribution of APOBEC3G 
alleles, 557G, -90C, 197C and 199G in the world almost mirrors that of HIV cases where the 
highest prevalence is in Sub-Saharan Africa where 67% of the HIV cases live compared to 
Europe (7%) and East Asia (10%) (Figure 4.1). This suggests that APOBEC3G genetic 
profile may have contributed to the differences in susceptibility or resistance to HIV infection 











Figure 4.1: The co-distribution of APOBEC3G variants and HIV in different populations. 
This is a world map showing the how APOBEC3G variants seem to follow the trend in HIV 
distribution. The big body in the middle is the African continent whilst the green and blue strip to 
the left shows the Americas (adapted from www.worldmapper.org).   














Despite the relationship between APOBEC3G variants and HIV prevalence in different 
populations, we did not observe any association between any of the APOBEC3G SNPs 
investigated in this study and risk of HIV infection. Our findings support observations by An 
et al. (2004), who in a multicentre study involving highly exposed seronegative and HIV 
seropositive individuals among African Americans and European Americans, also failed to 
observe any association between APOBEC3G variants and HIV status. Other studies on the 
557G>A SNP have reported no association between its variants and risk of HIV infection 
(Reddy et al. 2010, Valcke et al. 2006, De Maio et al. 2011). However, the 40683T allele of a 
C40693T SNP (rs17496018) in exon 4 of the APOBEC3G gene which did not form part of 
this study was associated with increased risk of HIV transmission (Valcke et al. 2006). These 
observations on APOBEC3G gene variation suggest that individual allelic variants may fail to 
show any effect on their own but their collective contribution to gene expression or overall 
protein structure may be important. 
In an effort to understand the combinational effect of APOBEC3G polymorphism on HIV 
transmission haplotype frequencies were compared between HIV infected and uninfected 
groups of children. LD analysis showed that only two variants, 557G and 197C which are 
positioned 177bp apart were in strong LD (r
2
=0.83) in the population. This is in contrast to 
studies in Argentinians, Caucasians and African Americans where all five SNPs investigated 
as part of  this study have been reported to be in strong LD (An et al. 2004, Bizinoto et al. 
2011). This is not surprising because African populations have been shown to exhibit very 
low LD blocks compared to other world populations because they are more genetically 














We compared haplotype frequencies and observed that the haplotype for C-G-G-C-C with 
regard to -571G>C, -90C>G, 557A>G, 197T>C and 199C>G SNPs was associated with 
increased risk of HIV infection as it occurred in 6% of the HIV-infected children but was not 
seen in the HIV-uninfected (P=0.007). A possible explanation for this observation is that the 
haplotype carries two promoter variants -571C and -90G which according to a predictive 
bioinformatics tool TFSearch (Heinemeyer et al. 1998) result in disruption of ADRI 
transcription binding sites which we speculate might interrupt with APOBEC3G expression. 
In addition, the haplotype contains the 557G allele which codes for the 186R variant in the 
APOBEC3G protein which results in reduced enzyme activity due to poor protein-protein 
structure. Therefore the C-G-G-C-C haplotype is likely to result in reduced antiviral activity 
of the APOBEC3G enzyme.  
Contrary to this haplotypes C-C-A-T-C and G-G-A-T-G were only observed in the HIV 
uninfected group suggesting they could be protective against HIV. In support of the 
explanation above, C-C-A-T-C and G-G-A-T-G carry only one transcription factor binding 
site altering variants each (either -571C or -90G and not both) and a 557A (H186) allele 
which means they have the correct amino acid at position 186 for protein-protein interaction 
and their expression is unlikely to be significantly altered. We therefore suggest that 
APOBEC3G haplotypes may have a significant role in HIV infection among the 
Zimbabweans. 
However, the effect of variation in the APOBEC3G gene on HIV outcomes depends on 
underlying factors such as the activity of other APOBEC proteins that also have antiviral 
properties (Henriet et al. 2009, OhAinle et al. 2006). For example, genetic polymorphisms 
and alternative splicing of APOBEC3F and APOBEC3H genes have been linked with 













The activity of APOBEC3G is also dependent on the functional activity of HIV Vif which 
antagonises the APOBEC3G antiviral properties by degrading the enzyme. APOBEC3G only 
exerts its antiviral effect in Vif deficient cells (Yu et al. 2004), thus, APOBEC3G variation 
does not matter in the presence of Vif.  A study by Gourrand et al. (2012) showed that 
haplotype variation in APOBEC3F made the enzyme differentially susceptible to suppression 
of its antiviral activity by Vif (Gourraud et al. 2011). HIV-Vif makes use of the host Cullin 5-
Elongin C E3 ubiquitin ligase complex to degrade APOBEC3G. Polymorphisms on the 
CUL5 gene that encodes the ligase complex have also been shown to affect HIV disease 
progression (An et al. 2007). Given this complex network of interaction of proteins in the 
cytidine deamination antiviral pathway, determination of association between APOBEC3G 
genetic variants and HIV infection or disease progression would require large sample sizes 
and adjusting for other proteins involved, a motivation for genome-wide association studies. 
Another innate immune factor MBL was also studied in addition to the APOBEC3G. 
4.3.2 MBL2 polymorphism 
Mannose binding lectin (MBL) is an acute phase protein involved in the non-specific 
response to invading micro-organisms through recognition of carbohydrate structures on their 
surface (Holmskov et al. 1994). MBL kills pathogens by activating the lectin pathway of the 
complement system, opsonisation, chemotaxis and/or direct killing (Vang Petersen et al. 
2001, Kuhlman et al. 1989). MBL recognises and binds to high mannose residues on HIV 
gp120 resulting in activation of the complement system to kill HIV (Ezekowitz et al. 1989). 
By binding the gp120, MBL also blocks the attachment of HIV to host cells bearing gp120 
receptors, thus, inhibiting infection of the host cell (Saifuddin et al. 2000). Deficiency in 













MBL deficiency is a result of low MBL2 gene expression and poor oligomerisation of MBL 
polypeptide units caused by polymorphism in the gene‟s promoter and exon 1regions 
(Boniotto et al. 2000, Garred et al. 2006). Therefore, this study investigated polymorphism in 
a 1187bp region of the MBL2 gene spanning the promoter and exon 1. 
Using the Sanger chain termination DNA sequencing, twelve polymorphic sites were 
detected in the region, one novel SNP, 10 previously reported and a multiple base deletion. 
We reported a new MBL2 -595G>A SNP with a minor allele (-595A) frequency of 2% in the 
Zimbabwean population. According to a predictive bioinformatics tool TFSearch, the 
polymorphism does not interact with any transcription factor binding site and may not play a 
significant role in MBL2 expression. We further investigated three of the four previously 
reported SNPs that have been linked with differential expr ssion and oligomerisation of the 
MBL to determine their possible role in HIV transmission and neurocognitive development.  
A frequency of 24% for the MBL2 170A allele in the Zimbabwean population was observed 
which is comparable to that observed among other Africans (20-30%) (Lipscombe et al. 
1992, Thye et al. 2011). The mutant alleles of MBL2 exon1 non-synonymous SNPs 170G>A 
(G57E), 154C>T (R52C) and 161G>A (G54D) are alternatively termed “C”, “D” and “B” 
respectively whilst the promoter and 5′-UTR variants -221C/G and +4C>T are termed -
221X/Y and +4P/Q respectively. Presence of any of the C, D or B allele is designated “O” 
allele while the wild-type is the “A” allele (Sumiya et al. 1991, Lipscombe et al. 1992, 
Madsen et al. 1994). The C, B and D alleles are unevenly distributed in populations of 
different ethnic origin (Garred et al. 2006). Thus, despite high frequency of the 170A allele in 
Zimbabweans and Africans in general, the allele is very rare in the both Asians (Ou et al. 













Out of the 26 samples sequenced in our study, neither 154T nor 161A alleles were observed 
yet the 154T occurs in 15% and 25% of Caucasians and Asians respectively whilst the 161A 
is rare in most populations (<5%) (Lipscombe et al. 1996, Chen et al. 2009).  
The uneven distribution of the 170A and 154T alleles in Caucasians and Africans does not 
seem to explain the differences in their HIV prevalences because the effect of the B and C 
alleles on MBL oligomerisation is almost the similar (Israels 2012). The resulting amino acid 
changes disrupt the α-helical structure of the MBL polypeptide chain, thus, interfering with 
the formation of functional oligomers (Eisen et al. 2003). This reduces the protein‟s antiviral 
activity and may increase susceptibility to a wide range of diseases.  
In the 5′-UTR, the MBL2 +4C (P) allele was observed in 45% of our study population which 
was comparable to what has been reported among other Africans (38-50%) but higher than 
that among Caucasians (17%) and Asians (12%) (Ou et al. 2011, Thye et al. 2011, Mangano 
et al. 2008). The distribution of the +4C allele in different populations suggests a possible 
contribution to the higher prevalence of HIV among Africans compared to Caucasians. 
However, this is contradicted by the lower frequency of the +4C among Asians (12%) 
compared to Caucasians (17%) because HIV prevalence is higher among Asians than 
Caucasians (Singh et al. 2008, Ou et al. 2011). In addition, the individual effect of the +4C 
allele on MBL2 gene expression has been reported to be mild and often overshadowed by -
221C>G variants (Israels et al. 2012).  
A frequency of the 12% for the -221C allele was observed which was in the same range with 
what has been reported among other Africans (12-17%), Caucasians (17%) and Asians (15%) 













We therefore speculate that -221C>G variants do not have a significant individual role in the 
distribution of HIV in different populations. Therefore, the distribution of individual MBL2 
variants does not comprehensively explain differences in HIV distribution in world 
populations.  
The distribution of MBL2 haplotypes, like that of the individual SNPs is uneven among world 
populations but it also does not show a trend that mirrors HIV distribution. MBL2 
polymorphism is likely to have been influenced by other micro-organisms more ancient than 
HIV. For example, the MBL2 170A (C) allele which results in MBL deficiency may have 
been selected for in African populations because it protects the host against MBL-mediated 
Mycobacterium africanum infection (Thye et al. 2011, Søborg et al. 2007). MBL-mediated 
opsonisation is used by some intracellular organisms such as M. africanum to enter host cells.  
Several other organisms have also been linked to MBL2 polymorphism (Eisen et al. 2003). In 
opposition of this linked to ancient organisms, reports on the evolutionary analysis of MBL2 
support neutral evolution involving migration and genetic drift to have shaped MBL2 allele 
distribution as opposed to natural selection (Verdu et al. ). It is also possible that because in 
addition to the lectin (MBL) pathway, complement system can also be activated by two other 
pathways (Endo et al. 2006) reduced MBL in circulation may not be detrimental to life, thus, 
unlikely to exert selective pressure (Mangano et al. 2008). To determine the possible effect of 
MBL2 variation on HIV infection in our study population, we compared genotype frequencies 
of 170G>A, -221C>G and +4C>T SNPs between HIV-exposed infected (EI) and exposed-















The homozygous +4C/C genotype was associated with increased risk of HIV infection 
compared to +4T/T and +4C/T genotypes but fell short of statistical significance (p=0.08). 
This can be explained by the down-regulatory effect of the +4C allele on MBL2 expression. 
The individual effect of +4C allele on HIV transmission has been down-played due the 
stronger effect of -221C>G and MBL2 A>O loci on MBL function (Mangano et al. 2008). 
However, our study provides evidence for an independent association of the +4C variant with 
HIV risk. When MBL2 genotypes at -221C>G, +4C>T and 170G>A loci where combined in 
a pair-wise fashion and their association with HIV status analysed the MBL2 -221G/G-4C/T 
combination was found to have a protective role against HIV infection as its frequency was 
significantly higher in the HIV EU group (44%) compared to the EI (22%) children (P=0.03). 
This is because the -221G and +4T alleles up-regulate MBL2 gene expression, thus, the -
221G/G-4C/T genotype is likely to encode sufficient MBL for antiviral activity.  
On the contrary, the +4C/C-170G/A genotype combination was associated with increased 
risk of HIV infection with borderline significance (p=0.06). The +4C/C-170G/A genotype 
carries alleles that both down regulate MBL2 expression (+4C) and interrupt MBL 
multimetrisation making an MBL deficiency genotype. This leads to impaired MBL-
mediated complement activation, viral opsonisation and killing, thus leaving the body 
exposed to HIV infection (Garred et al. 2006, Saifuddin et al. 2000). Our observations are 
supported by reports that MBL deficiency variants such as MBL2 O/O and MBL2 XA/XA may 
be strong risk factors for HIV infection compared to MBL sufficiency variants (Kuhn et al. 
2006, Boniotto et al. 2003). Others have reported accelerated disease progression in 
individuals carrying MBL deficiency variants (Singh et al. 2008, Mangano et al. 2008). A 
study among Americans reported that MBL deficiency due to genetic polymorphism had a 













4.4 Genotype Combinations and HIV infection 
HIV/AIDS is a multifactorial condition affected by several pathways in the innate and 
adaptive immune systems. Several antiviral factors work simultaneously in an attempt to 
mount immunity against HIV. Therefore, co-occurrence of HIV/AIDS restriction gene 
variants in an individual may give an amplified effect compared to the individual SNPs. 
Given this, genotypes of some SNPs were combined in a pair-wise fashion to determine their 
possible role in HIV infection.  
The frequency of CCR2 190G/A-CX3CR1 745G/G genotype combination was significantly 
(P=0.002) higher in HIV EU children (33%) than EI children (0%) suggesting that this 
genotype combination may be having a protective role against HIV infection (Table 3.9). 
This observation and reasoning is supported by the functional roles of alleles in the individual 
genotypes. The CCR2 190A has been reported to confer a protective role by facilitating the 
dimerization of the CCR2 64I protein to CXCR4 making CXCR4 less available for HIV 
attachment. The allele has been reported to act in a dominant manner where its presence even 
in a heterozygote is fully expressed. The protein product of CX3CR1 745G (249V) has 
stronger capacity to bind to fractalkine compared to the 249I, resulting in a stronger 
chemotactic effect conferring a more viable immune response. The combined effect of these 
two protective mechanisms may account for the HIV resistance exhibited by individuals 















The CCR2 190G/A-APOBEC3G 557A/A combination was associated with low risk of HIV 
infection as it occurred in 17% of the HIV EU individuals whilst it was absent in the HIV EI 
group (P=0.015) (Table 3.9). APOBEC3G 557G variant has been associated with accelerated 
disease progression (An et al. 2002, Reddy et al. 2010), thus, the APOBEC3G 557A variant 
may be protective against HIV as it gives the correct amino acid configuration for protein-
protein interaction of APOBEC3G enzyme in a reversal of the mechanism discussed earlier. 
The CCR2 190G/A as mentioned earlier carries the protective 190A allele. Therefore, our 
study points out that given a CCR2 190G/A background, the protective effect of 557A/A may 
reduce risk HIV infection.  
In contrast, CX3CR1 745A/A-RANTES In1.1T/T genotype was significantly higher in HIV EI 
children (10%) compared to the EU (0%) suggesting that it might be a risk factor for HIV 
infection (p=0.05) (Table 3.9). Paradoxically RANTES In1.1T allele has been described to up-
regulate the expression of RANTES therefore making available more of the chemokine for 
competitive inhibition of HIV binding. Despite this, Rathore et al. (2008) reported the In1.1T 
to be a risk factor for HIV infection (Rathore et al. 2008). Our study supports Rathore‟s 
observation but on a CX3CR1 745A/A genotype background. The CX3CR1 745A/A genotype 
background has a villain role in HIV infection where its resultant protein has weaker binding 
to its ligand and therefore poor immune activation. Genotype combinations are therefore 
more likely to have an effect on HIV-infection compared to individual SNPs because of the 
















4.5 Genetic polymorphism and neurocognitive function  
Neurocognitive impairments ranging from mild cognitive deficits to HAD are a common 
feature in HIV/AIDS patients (Heaton et al. 2011). Although HIV enters the CNS in the early 
stages of infection neurocognitive complications only surface later when the clinical state of 
the patient deteriorates (Gendelman et al. 1997, Hazleton et al. 2010). This suggests that 
neurocognitive impairments in HIV maybe a result of disease progression. There seems to be 
inter-individual variation in the susceptibility and prognosis of neurocognitive disorders even 
in patients who are on ART. A fraction of HIV-negative children also experience 
neurocognitive impairments suggesting that etiological factors other than HIV are at play 
(Bagenda et al. 2006). We therefore investigated the relationship between genetic variation 
and neurocognitive function in HIV-infected and HIV-uninfected children.   
We observed a general tendency to poor neurocognitive performance in HIV-infected 
children compared to the uninfected (Table 3.10). This is not surprising as presence of HIV 
protein such as gp120 and Tat in the central nervous system causes microglia and astrocytes 
to secrete neurotoxins that result in neuronal damage (Strazza et al. 2011, Fritz-French et al. 
2012). HIV patients are also at risk of developing encephalitis due to cytokine overexpression 
and opportunistic infections such as cytomegalovirus, Epstein-Barr virus and others (Strazza 
et al. 2011, Polilli et al. 2010). These are likely to interfere with neurological function 
resulting in HIV-associated neurocognitive disorders. Our observations are supported by 
other reports on higher risk of neurocognitive impairments among HIV-infected children 














Other factors such as nutrition, family and general environment have been reported to 
influence cognitive ability in children (Boivin et al. 1995, Eskenazi et al. 1999, Mendola et al. 
2002). However, the focus of our study was the association between genetic variation and 
neurocognitive impairment. 
We found the frequency of APOBEC3G -90C/G and MBL2 170G/A (A/C) significantly 
higher in children exhibiting poor cognitive ability compared to those with normal cognitive 
ability (P=0.048 and 0.046 respectively) among HIV infected children. These observations 
suggest that APOBEC3G -90C/G and MBL2 170 G/A genotypes are possible risk factors for 
neurocognitive impairment in HIV-infected children compared to the APOBEC3G -90G/G 
and MBL2 G/A respectively. APOBEC3G and MBL are both innate immune factors involved 
in antiviral activities against HIV. To our knowledge there is no evidence in literature linking 
APOBEC3G -90C>G variants to HIV-associated neurocognitive impairment. However, the 
APOBEC3G -90C/G may be involved in the differential expression of the APOBEC3G 
protein and studies have linked low APOBEC3G protein levels to faster HIV disease 
progression (Jin et al. 2007). Another possibility is that since deficiency of apolipoprotein B 
containing lipoproteins in serum leads to peripheral neuropathy (Rampoldi et al. 2002) and 
APOBEC3G is an apolipoprotein B mRNA enzyme there could be a link to neurocognitive 
ability.  
The association between MBL2 170G/A genotype and neurocognitive impairment in HIV-
infected children can be explained by the MBL deficiency resulting from carrying the 170A 
(C) allele (Garred et al. 2006). This observation is supported by reports of a tendency towards 
neurocognitive impairment among American HIV-infected children with the MBL2 O/O 













Another study also reported an association between O/O genotype and increased risk of 
neurocognitive decline among Chinese HIV-infected adults compared to the A/A genotype 
(Spector et al. 2010), However, a recent genome wide association study (GWAS) on an adult 
population did not find any SNP to be associated with neurocognitive impairment and/or 
HAD (Levine et al. 2012)(). In addition to the possible role of MBL2 polymorphism in 
neurocognitive function in HIV-infected children, we also observed its effect among the 
HIV-negative children. 
We report a significantly higher frequency of the MBL2 +4C/C (P/P) and -221C/G (X/Y) 
genotypes in HIV-uninfected children who are verbally impaired compared to the HIV 
negative verbally unimpaired (P=0.03 and 0.05 respectively) (Table 3.11). MBL2 -221C/G 
was also observed more frequently in HIV-uninfected children with a general NCI score 
below 68 when compared to those above 68. These observations provide evidence that +4C/C 
and -221C/G genotypes are possible risk factors for neurocognitive impairment regardless of 
HIV status. The -221C allele is associated with MBL deficiency which may allow infection 
by micro-organisms that target the CNS (Garred et al. 2006). A study among Chinese HIV-
negative adults reported an association between the MBL deficiency O/O genotype and 
cryptococcal meningitis (Ou et al. 2011) further supporting our observation that MBL2 
polymorphism may affect neurocognitive outcomes regardless of HIV status. We therefore 
report a possible role of MBL2 polymorphism in both HIV-associated and HIV-free 
neurocognitive status. Our study makes a great contribution towards understanding host 
genetic variation with regards to HIV infection and neurocognitive development among 















4.6  Limitations of the study and potential redress 
The major challenge in our study was the limited sample size. We could not do anything to 
increase the number of HIV-exposed infected children because the study drew samples from 
a decade long cohort and numbers were restricted to participants who were accessible and 
meeting the inclusion criteria. However, to boost the sample size, a 1:2 ratio of HIV positive 
to HIV negative was used. This allowed for allele frequencies to be approximated more 
accurately as evidenced by the fact that allele distribution in our control population 
conformed to Hardy Weinberg Equilibrium for all SNPs studied meaning there was no 
apparent sampling bias. 
 In addition to sample size, another limitation of the study was the possibility of survivor bias 
in our study population. Since the study population was limited to individuals alive after 
close to a decade of follow-up, information on the genetic make-up of those children who 
died during follow-up period was not available. This means that comparison of genotype and 
allele frequencies between HIV-exposed infected and HIV-exposed uninfected might not be a 
correct approximation of the relationship between genetic variation and risk of HIV infection. 
A large fraction of HIV-infected children succumb to effects of the virus before the age of 
five. It can be speculated that if any genetic variants are associated with faster disease 
progression and possible death then these could have been reduced more in the available 
HIV-infected population compared to the uninfected after nine years of follow-up.   
It has also been argued that maternal virological, immunological and genetic factors may 
influence the chances of a mother transmitting HIV to their child. Mothers exhibiting 
advanced clinical signs and symptoms are more likely to transmit HIV to their children 













Differences in maternal viral loads mean that children‟s exposure to HIV during pregnancy, 
birth and breastfeeding is different and therefore may determine the risk of infection despite 
child‟s genetic make-up. HIV co-infections such as STIs, malaria and TB may also increase 
chances of a mother transmitting HIV to their child (Gumbo et al. 2010, Gupta et al. 2011, 
Kliks et al. 1994). Depleted immunological status of the mother as reflected by low CD4+ T- 
cell count also indicates increased exposure to HIV (Singh et al. 2009). These factors, if 
considered in a study like ours could have given a more holistic picture. 
The role of host genetic variation in HIV transmission could have been elucidated better if 
maternal genetics had also been included in the study. It has been shown that KIR-HLA 
heterogeneity between mother and child influenced the risk of vertical transmission of HIV 
(Paximadis et al. 2011). Reports among Kenyans show that infants were more likely to be 
infected perinatally by HIV if the mother had the SDF1 801G/A genotype (Mabuka et al. 
2009). It would be important to consider maternal genetic variation in future work. 
4.7 Conclusion and future prospects 
Despite the mentioned limitations our study makes a huge contribution in understanding the 
genetic correlation of HIV infection and neurodevelopmental deficits. Our findings pave way 
for larger and more focused studies taking a genomics rather than a candidate gene approach. 
It is learnt from our findings that host gene variants are more likely to work together as 















RANTES, CX3CR1and APOBEC3G variants did not show association with HIV infection 
when analysed individually but combination of genotypes that enhance their antiviral 
activities where more frequent in the HIV-exposed uninfected children than the infected 
strongly arguing for a synergistic antiviral effect. This combinational effect points to critical 
pathways in HIV infection that may be exploited for therapeutic benefits. 
HIV is a multifactorial condition where different immune pathways work simultaneously 
with a possibility of masking or enhancing one another. We therefore recommend that future 
work takes advantage of advances in DNA technology such as microarrays and next 
generation sequencing to carry out GWAS on HIV and HIV-related outcomes. Protein 
profiling to confirm effect of polymorphism on disease outcomes is also recommended to 
enhance the interpretation of raw DNA sequences. Prot omics and transcriptomes have 
shown new pathways involving the dysregulation of gene expression due to presence of HIV 
in the host (Kartvelishvili et al. 2004) so there is need to integrate genetic variants and their 
resultant protein profiles.   
We observed an association between MBL2 gene variants and neurocognitive function 
regardless of HIV suggesting that gene variants that regulate the immune system are a 
potentially useful tool in predicting the outcome of neurodevelopmental status and diseases. 
Due to the wide use of ART, children who are perinatally infected by HIV now have a good 
chance to survive into adulthood therefore MBL2, chemokine and chemokine receptor 
variants can be assembled into a predictive tool for HIV-related and neurocognitive 
outcomes. This way, the vulnerable or high risk individuals can be identified and monitored 
closely. An accurate correlation of clinical, genetic and immunological profiling in such cases 
could prove useful in prioritising care. We therefore recommend more research goes into the 













A novel MBL2 -595G>A SNP was observed after sequencing 1187bp in the MBL2 gene. It 
can be deduced from this observation that there may be more undetected gene variants in 
African populations as most have not been studied at genome level. These SNPs may be able 
to answer some disease related questions in the African population. This further argues for 
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Appendix C: Correlation between Haemoglobin levels and human genetic variation 
regardless of HIV status 




Odds Ratio  P-value 
CCR2 190G>A; rs17141036       
190G/G 8 (0.80) 50 (0.68)  1.92 (0.34-0.20)  0.42 
190G/A 2 (0.20) 21 (0.28)  0.63 (0.06-3.56)  0.58 
190A/A 0 (0.00) 3 (0.04)  -  0.52 
     
CX3CR1 745G>A; rs3732379         
745G/G 7 (0.70) 61 (0.84)  0.46 (0.09-3.17)  0.30 
745G/A 2 (0.20) 11 (0.15)  1.41 (0.13-8.49)  0.69 
745A/A 1 (0.10) 1 (0.01)  8 (0.09-636)  0.09 
          
RANTES In1.1T>C;rs2280789       
In1.1T/T 8 (0.89) 42 (0.57)  1   
In1.1T/C 1 (0.11) 30 (0.40)  0.18 (0.00-1.51)  0.08 
In1.1C/C 0 (0.00) 2 (0.03  -  0.17 
RANTES -403G>A; 2107538         
-403G/G 1 (0.10) 20 (0.27)  0.3 (0.01-2.44)  0.24 
-403G/A 8 (0.80) 42 (0.57)  3.05 (0.55-31.02)  0.16 
-403A/A 1 (0.10) 12 (0.16)  0.57 (0.01-4.91)  0.61 
     
A3G 197T>C; rs3736685        
197T/T 4 (0.40) 28 (0.38)  1.10(0.21-5.09)  0.89 
197T/C 4 (0.40) 34 (0.46)  0.78 (0.15-3.64)  0.72 
197C/C 2 (0.20) 12 (0.16)  1.29 (0.12-7.68)  0.76 
A3G -571G>C;rs5757463         
-571C/C 5 (0.50 57 (0.85)  0.17 (0.03-0.94)  0.01 
-571C/G 5 (0.50) 10 (0.15)  5.7 (1.06-29.17)  0.01 
-571G/G 0 (0.00) 0 (0.00)     
A3G -90C>G; rs5750743         
-90C/C 1 (0.10) 9 (0.10)  0.81 (0.02-7.29)  0.85 
-90C/G 3 (0.30) 34 (0.47)  0.52 (0.08-2.5)  0.36 
-90G/G 6 (0.60) 32 (0.44)  2.02 (0.43-10.46)  0.30 
A3G 557A>G; rs8177832        
557A/A 3 (0.30) 27 (0.37)  0.73 (0.11-3.55)  0.67 
557A/G 5 (0.50) 34 (0.47)  0.72 (0.17-2.78)  0.59 
557G/G 2 (0.20) 12 (0.16)  1.27 (0.12-7.56)  0.78 
A3G 199C>G;rs2294367         
199C/C 8 (0.89) 62 (0.91)  0.77 (0.08-40)  0.82 
199C/G 1 (0.11) 5 (0.07)  1.58 (0.03-16.92)  0.69 













Appendix D: Comparison of demographic features between HIV exposed uninfected and 
HIV unexposed uninfected groups 
Characteristics HIV EU   HIV UEUI P-value 
Mean age in years  
±Stdev (range) 
8.11±0.47(7.5-9.08) 8.74±0.45(7.5-9.08) 1.00 
    
Mean height in cm  
±Stdev (range) 
121.43±5.44(111-132) 119.32±6.42(108-133.5 0.168 
    
Mean weight in kg 
±Stdev (range) 
22.53±2.80(16-27) 22.16±3.35(15-30.5) 0.646 
    
Mean head circum in cm 
±Stdev (range) 
51.39±1.28(48-54) 51±1.19(49-54) 0.949 
    
Body mass index n=31 n=31  
Normal (5-85%) 28 (0.90) 27 (0.87)  
Underweight (<5%) 3 (0.10) 4 (0.13) 0.688 
    
Sex n=36 n=36  
Female 17 (0.47) 19 (0.53)  
Male 19 (0.53) 17 (0.47) 0.637 
    
Haemoglobin n=34 n=31  
Normal (11-16g/dL) 30 (0.88) 28 (0.90)  
Low (<11g/dL) 4 (0.12) 3 (0.10) 1.00 
    
Morbidities    
Diarrhoea n=36 n=36  
No 31 (0.80) 28 (0.78)  
Yes 5 (0.14) 8 (0.22) 0.358 
Ear Discharge    
No 35 (0.97) 32 (0.89)  
Yes 1 (0.03) 4 (0.11) 0.357 
Vomiting    
No 32 (0.89) 29 (0.81)  
Yes 4 (0.11) 7 (0.19) 0.514 
Cough    
No 21 (0.58) 23 (0.64)  
Yes 15 (0.42) 13 (0.36) 0.629 
Fever    
No 22 (0.61) 21 (0.58)  














Appendix E: Conference acceptance letters and abstracts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
